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Shelterin is an essential telomeric protein complex that prevents DNA 
damage signaling and DNA repair in a compartmentalized manner. We assessed 
contributions of the conserved shelterin component, Rap1, to telomere end-
protection. Rap1 was first discovered in budding yeast as a transcription factor 
and was later shown to bind directly to telomeres. Two important functions of 
Rap1 in yeast are: the negative regulation of telomere length, and the inhibition of 
the double-strand break (DSB) repair pathway non homologous end-joining 
(NHEJ). Mammalian Rap1 interacts with shelterin factor TRF2, to localize to 
telomeres, and human Rap1 is implicated in repressing NHEJ. 
Surprisingly, removal of Rap1 from telomeres revealed that mouse Rap1 
was not required to inhibit NHEJ, but instead was critical for the repression of the 
DSB repair pathway homology directed repair (HDR). We showed that complex 
formation of Rap1 and TRF2 was most likely necessary to repress HDR, 
although the mechanism of how it does so remains to be determined. 
Two discrepancies exist between mouse and human Rap1 regarding 
repression of NHEJ and regulation of telomere length. Human Rap1 was 
proposed to inhibit NHEJ, but we observed no evidence of telomere fusions in 
the mouse Rap1 knockout. Similarly, telomere elongation was observed upon 
knockdown of human Rap1, but no telomere length phenotypes were observed in 
Rap1-deficient mice. With the advent of new genome-editing technologies that 
facilitate targeting in human cells, we constructed TALEN-mediated knockouts of 
human Rap1 in numerous cell lines. Loss of human Rap1 did not lead to an 
induction of NHEJ, or show consistent changes in telomere length, indicating that 
similar to mouse Rap1, human Rap1 does not have an important function in 
protection or length regulation of human telomeres. Instead, we found that 
mammalian Rap1, like its unicellular orthologs, affects gene expression. 
Therefore, perhaps the conservation of Rap1 reflects its role in transcriptional 
regulation rather than a function at telomeres. 
Organismal discrepancies regarding the function of shelterin components, 
other than Rap1, also exist. Targeting of human shelterin component POT1 
(POT1a/b in the mouse) with shRNAs shows a reduction in 3’ telomere 
overhangs and a mild induction of DNA damage signaling. However, deletion of 
mouse POT1a and –b results in extended 3’ overhangs and a massive induction 
of the DNA damage response. To understand the role of human POT1 in 
telomere protection, we used TALENs to generate human knockout cell lines 
lacking POT1. We found that similar to mouse POT1, deletion of human POT1 
elicited significant DNA damage signaling. Strikingly, the amount of 3’ single-
stranded DNA remained unchanged upon loss of POT1, highlighting a potential 
difference in overhang regulation between mice and humans. 
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Chapter 1: Introduction 
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1.1 The structure and function of telomeres 
Telomeres are conserved nucleoprotein structures comprised of short 
tandem repetitive sequences and highly specific binding proteins that allow linear 
DNA to evade recognition as double-stranded breaks (DSBs). Telomeres derive 
their name from telos (end) and meros (part) after Hermann Muller irradiated 
Drosophila melanogaster and noted that he never found mutants with deletions 
or inversions that involved the natural ends of chromosomes 1. Independently, 
Barbara McClintock observed from her expansive work in Zea mays that unlike 
the natural ends of chromosomes, the ends of broken chromosomes were prone 
to cycles of fusion and breakage, which were only halted in zygotes where 
broken ends were able to ‘heal’ 2. These early observations illuminated special 
features of chromosome termini that preserve genomic integrity.   
Telomere repeats vary in sequence and length, with a unifying feature 
being the G-rich nature of the strand that runs from 5’ to 3’ to the telomere 
terminus. In general the telomere ends in a 3’ single-stranded (ss) overhang. 
Budding and fission yeasts have short telomeres of several hundred base pairs 3, 
while mammals have much longer telomeres ranging from 10-15 kb in humans 4 
and from 20-50 kb in mice (Figure 1.1) 5,6. 
Mammalian telomeric TTAGGG repeats 7-9 are bound by a six (seven in 
mouse) subunit protein complex termed shelterin (reviewed in 10). Shelterin 
consists of two double-strand (ds) DNA binding proteins, TRF1 and TRF2 11-14. 
TRF1 and TRF2 have similar homodimerization (TRFH) domains and both form 
3 
homodimers that bind two copies of the half site 5’-YTAGGTTR-3’ using their C-
terminal Myb/SANT domains 15-17. The two proteins differ in their N-terminus 
where TRF1 has an acidic domain while TRF2 has a basic domain 16. A central 
region comprised minimally of 41 amino acids, present in TRF2 18,19, but not 
TRF1, recruits Rap1 to the telomere 20. Rap1 forms a 1:1 complex with TRF2 21,22 
using its C-terminus 23, and requires this interaction not only for its localization to 
the telomere 24. TRF1 and TRF2 both bind to TIN2 21,25-27, which serves as a 
bridge between the telomeric double-strand and single-strand binding proteins. 
TIN2 binds to TPP1 26,28,29, which forms a heterodimer with the ssDNA binding 
protein POT1 30 (POT1a and POT1b in the mouse) 31,32. POT1 binds to the 
telomeric 3’ overhang via its oligonucleotide/oligosaccharide binding (OB) 
domains with the minimal binding site 5’-TTAGGGTTAG-3’ 33,34. 
The telomeric protein complex of the fission yeast Schizosaccharomyces 
pombe (sp) resembles mammalian shelterin in that it contains Taz1 35, a TRF 
ortholog that binds to duplex DNA and recruits spRap1 36. Bridging proteins Poz1 
and Tpz1, proposed to be functional analogs of TIN2 and TPP1, serve to link 
Taz1/Rap1 to the ssDNA binding protein POT1 30,37. The highly diverged 
protozoa Trypanosoma brucei (tb) also has a TRF homolog (tbTRF) that binds 
telomeres and recruits tbRap1 38,39. Budding yeast however does not have a 
TRF/Taz-like protein at telomeres or a POT1 ortholog. Instead, Rap1 is the de 
facto telomere dsDNA binding protein in Saccharomyces cerevisiae (sc) 40-42. 
The single-stranded 3’ overhang in S. cerevisiae is bound by the CST (Cdc13, 
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Stn1, Ten1) complex 43, which modulates telomere length, recruits telomerase 
and protects the telomere terminus 44-47. S. pombe contains Stn1 and Ten1 that 
bind to ssDNA and are required for telomere protection 48. A similar CST 
complex, originally identified as an accessory factor of DNA polymerase α-
primase 49,50, also exists in mammalian cells where its subunits are referred to as 
CTC1, Stn1 and Ten1. Mammalian CST participates in overhang maintenance 51 
52,53, but its function is different from budding yeast and its recruitment to 
telomeres is mediated by TPP1 and POT1 52,54. Despite the divergent nature of 
these complexes, they all perform the same function – the maintenance and 
protection of telomeres.   
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Figure 1.1 Telomere binding complexes in mammals and yeast. Telomere sequence repeats 
and associated binding complexes are depicted here. Approximate telomere lengths for duplex 
DNA and single-stranded overhang are indicated below. 
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1.2 Threats to chromosome termini  
Chromosome ends face two ominous threats referred to as the end-
replication problem and the end-protection problem. The end-replication problem 
originates from the inability of DNA replication to fully synthesize the 3’ ends of 
linear DNA, which would result in shorter telomeres with every cell division 
thereby limiting the replicative potential of the cell 55-57. The end-protection 
problem refers to the propensity of chromosome ends to be recognized as a 
DSB, which would result in disastrous consequences such as cell cycle arrest or 
apoptosis if DNA damage signaling and DSB repair were inappropriately 
activated (reviewed in 58).  
1.2.1 Telomerase counteracts the end-replication problem 
Semi-conservative DNA replication involves two modes of DNA synthesis, 
leading- and lagging-strand synthesis. In leading-strand synthesis, the 
polymerase moves in the same direction as the replication fork allowing the 
molecule to be replicated to the very end, presumably resulting in a blunt end. In 
lagging-strand synthesis, DNA is synthesized in the opposite direction to the 
replication fork, necessitating RNA primers to initiate DNA synthesis in short 
stretches known as Okazaki fragments that are eventually ligated together once 
the RNA primers have been removed (reviewed in 59). At a DNA end, lagging-
strand synthesis could be incomplete due to lack of priming for the most distal 
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Okazaki fragment or due to removal of the most distal RNA primer, thus resulting 
in loss of the terminal sequence in the daughter cell 60.  
In 1961 Leonard Hayflick noted that normal human fibroblasts are able to 
divide in culture for a limited number of (between 40-60) population doublings 
(PDs), after which they senesce 57. This proliferative barrier was termed the 
Hayflick limit. Further work has illustrated that this phenotype was likely due to 
telomere shortening, and in order to bypass replicative senescence, cells with 
limiting telomere lengths require a mechanism by which telomere length can be 
maintained 61. While fibroblasts tend to senesce with approximate telomere 
lengths of 5-7 kb, it is unclear what the minimal length requirement is for proper 
telomere function (reviewed in 62).  
One solution to the end-replication problem is provided by telomerase, a 
ribonucleoprotein enzyme. The telomerase RNA component, TERC or TR, 
serves as a template for synthesis of the G-rich telomeric strand by the catalytic 
subunit TERT (telomerase reverse transcriptase). The prediction that a terminal 
transferase-like activity extended chromosome ends was based on the ability of 
yeast to maintain linearized plasmids containing ciliate telomeres, by addition of 
repetitive G-rich sequences 63. The RNA component of telomerase was cloned 
from the ciliate Tetrahymena 64. Genetic screens in S. cerevisiae for senescence 
mutants that displayed progressive telomere shortening 65,66, alongside 
biochemical fractionation of factors that co-purified with telomerase activity in 
Euplotes aediculatus 67 led to the discovery of the telomerase catalytic subunit 
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Est2 (ever shorter telomeres 2). Following this discovery, mammalian 
components of telomerase were rapidly identified 68-70. Indeed genetically 
engineered mice lacking TERC display shortening telomeres over several 
generations and exhibit chromosomal abnormalities by the fourth generation 71. 
In human cells telomerase is expressed in the germline, but not in most 
somatic tissues 72. However, telomerase activity is readily detectable in 
immortalized human cell lines that have either been transformed 73 or derived 
from tumors (reviewed in 62). Approximately 90% of tumour biopsies tested were 
shown to express telomerase 74. Lack of telomerase expression in somatic 
tissues suggests that limiting the replicative potential of a cell acts as a barrier to 
tumor development, and premalignant or malignant cells must reactivate 
telomerase or use an alternative method of telomere length maintenance to 
acquire their immortal properties.  
Examination of other mammals such as elephants and whales indicated 
they have similar telomere lengths to humans and no telomerase activity in 
somatic cells. In contrast to these large long-lived mammals, mice and other 
short-lived mammals such as shrews and opossums have longer telomeres than 
humans and constitutive telomerase activity 6. Gomes et al. noted that 
telomerase activity and telomere length generally correlated inversely with body 
size and lifespan, giving rise to the proposal that animals with a short lifespan 
accrue a lower mutational load and therefore may not require replicative aging as 
a tumor suppressor mechanism. It is clear that while telomerase is necessary to 
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counteract the end-replication problem, its expression and activity must be 
meticulously controlled. 
1.2.2 Telomere length regulation by telomere-binding proteins 
Initial insights into the mechanism of telomere length regulation were 
derived from studies in S. cerevisiae where increasing the number of scRap1 
binding sites resulted in proportional shortening of the telomere 75. Thus a cis-
acting protein-counting mechanism was proposed where telomere-repeat 
addition by telomerase was inhibited based on the number of Rap1 molecules 
bound to the telomere. In agreement with these results, overexpression of TRF1 
in a subclone of HT1080s (HTC75; a human fibrosarcoma telomerase-positivie 
cell line) led to telomere shortening, while expression of a dominant negative 
mutant of TRF1 (TRF166-385) that diminished TRF1 at telomeres resulted in 
telomere elongation 76. Overexpression of TRF2 also led to telomere shortening 
and telomerase activity was not affected by TRF1 or TRF2 76,77. Thus the two 
dsDNA binding proteins negatively regulate telomere length through a similar 
‘protein-counting’ mechanism as shown in yeast 75. Similarly, when double-strand 
telomere binding protein Taz1 was deleted in S. pombe, negative regulation of 
telomere length was abolished. Interestingly, when spRap1 was deleted, 
telomeres also elongated 36, suggesting that recruitment to telomeres, as 
opposed to direct binding to telomeres, might be sufficient for telomere length 
control. 
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Surprisingly, overexpression of human Rap1 leads to telomere 
lengthening 20, but this elongation is observed even when a Rap1 mutant 
defective in localization to the telomere is overexpressed 23. Considering the 
large nucleoplasmic pool of Rap1 that accumulated when exogenously 
expressed, it was hypothesized that the non-telomeric Rap1 titrates away a 
telomere-associated factor involved in length regulation, that otherwise along with 
Rap1 would inhibit telomere elongation. Mild extension of telomeres after partial 
knockdown of Rap1 in HTC75 cells provided further support for Rap1 as a 
negative regulator of telomere length 78. 
Telomeres also elongated when POT1 binding to ssDNA was inhibited by 
expression of a POT1 mutant lacking its OB fold, POT1ΔOB 79. Furthermore, TIN2 
and TPP1 levels reduced by shRNAs 80 29 and expression of TIN2 mutants that 
could not bind TPP1 25 resulted in telomere elongation, illustrating that 
recruitment of POT1 is required for negative regulation of telomere length. 
However, TPP1 and POT1 have also been implicated in the positive regulation of 
telomerase. The TPP1/POT1 heterodimer was shown to enhance telomerase 
processivity in vitro 81, with telomerase acting preferentially on substrates coated 
with POT1/TPP1 82. In addition, the OB fold of TPP1 can bind to and recruit 
TERT to telomeres 81,83-85. Specifically, a group of surface-exposed amino acids 
in the OB fold of TPP1, referred to collectively as the TEL patch, is required for 
recruitment and activation of telomerase 86,87. 
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1.2.3 The end-protection problem 
The integrity of the genome is constantly threatened by internal processes 
such as errors introduced during DNA replication and external sources such as 
genotoxic agents of radiation. Various mechanisms are in place to detect 
damaged DNA, collectively referred to as the DNA damage response (DDR), and 
to fix these lesions with DNA repair pathways. Mammalian DDR signaling occurs 
primarily through two kinases, the ATM (ataxia telangiectasia mutated) kinase, 
activated by the MRN (Mre11-Rad50-Nbs1) complex that senses DSBs, and the 
ATR (ATM and Rad3 related) kinase that is activated by the binding of 
Replication Protein A (RPA) to ssDNA (reviewed in 88). Chromosome ends are 
vulnerable to both of these pathways with the telomere terminus being 
recognized by ATM and the single-stranded overhang being a substrate for ATR 
activation. 
Activation of ATM and/or ATR triggers cell-cycle checkpoints by 
phosphorylation of downstream effectors Chk2 89-91 and Chk1 92,93 respectively, 
that phosphorylate Cdc25 phosphatases 94, which in turn act to reduce the 
activity of cyclin-dependent kinases (CDKs), thereby leading to rapid cell-cycle 
arrest in intra-S or G2/M 95,96. Phosphorylation of p53 97-100 and downstream 
signaling also occurs to initiate a delayed response to DNA damage, leading to 
cell cycle arrest at the G1/S transition and senescence or apoptosis. These 
processes are thought to allow time for DNA repair to occur and prevent 
transmission of damaged DNA to daughter cells. Coupled with checkpoint 
 12 
activation, signaling by ATM and ATR also promotes a localized response at the 
site of the lesion by recruitment and/or activation of DNA repair factors. Both 
ATM 101 and ATR 102 phosphorylate histone H2AX (γH2AX) in chromatin proximal 
to the damaged lesion. MDC1 (Mediator of DNA damage checkpoint 1) binds to 
γH2AX and serves to amplify the DNA damage response 103-105. Subsequent 
recruitment of E3 ubiquitin ligase RNF168 leads to ubiquitylation of lysine 15 on 
histone H2A or H2AX 106 resulting in recruitment of the DNA repair effector 
53BP1 (tumor suppressor p53 binding protein 1) 107. These DNA damage 
response proteins are not normally detected at the telomere; however, upon 
induction of telomere damage, H2AX becomes phosphorylated in the telomeric 
chromatin and DNA repair factors such as 53BP1 accumulate at the telomere. 
These indices of local DNA damage signaling are frequently used as readouts for 
telomere dysfunction 108,109. 
DSB repair occurs through two major pathways, non homologous end-
joining (NHEJ) and homology-directed repair (HDR). NHEJ is the main method of 
repairing breaks in the G1 phase of the cell cycle, while HDR predominates in 
S/G2 when the presence of a sister chromatid can provide a template for error-
free repair. Two forms of NHEJ have been described: classical- and alternative- 
NHEJ (c-NHEJ and alt-NHEJ 110,111). Essential components of c-NHEJ 112 consist 
of the Ku70/80 heterodimer which binds to DSBs 113,114, and DNA Ligase IV 
(Lig4) which is responsible for ligating the ends 115. Alt-NHEJ on the other hand is 
promoted by PARP1 (poly adenosine diphosphate ribose polymerase 1) 116, 
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requires resection of the DNA end, and then makes use of small 
microhomologies and DNA Ligase 3 (Lig3) 117 to ligate the ends. Ku70/80 has 
been shown to inhibit alt-NHEJ, potentially by competing with PARP1 for DSBs 
118. Both types of NHEJ have been shown to be active at dysfunctional telomeres 
24,119-121. Inappropriate repair of chromosome ends by NHEJ results in fused 
dicentric chromosomes that are unstable in mitosis and can initiate breakage-
fusion-bridge (BFB) cycles thereby leading to genomic instability 2.  
The central tenets of HDR are resection of a 5’ end to generate a 3’ 
ssDNA overhang, formation of the Rad51 (radiation sensitive 51) filament to 
conduct a homology search, followed by strand invasion into a homologous 
region to initiate DNA repair (Figure 1.2). Termination of the telomere in a 3’ 
single-stranded overhang makes it primed for HDR. 
The MRN complex has been implicated in promoting DSB resection in 
cooperation with CtIP 122, as well as BRCA1 (breast cancer 1) 123. In addition, 
Exo1, a 5’ to 3’ exonuclease, in concert with Bloom (BLM), a member of the 
RecQ helicase family, have also been shown to mediate resection at DSBs 
124,125. Following resection, the current model derived from studies in yeast is that 
RPA initially coats the available ssDNA to facilitate assembly of the presynaptic 
filament and remove secondary structures within the ssDNA 126-128. Mediator 
protein BRCA2 (breast cancer 2) subsequently assists in displacement of RPA 
and loading of Rad51 to form the pre-synaptic filament 129-131. Following strand 
invasion into the region of homology and DNA synthesis, ‘second end capture’ 
14 
can then occur where the strand not involved in initial invasion is captured to form 
a double Holliday junction (dHJ). If this dHJ is dissolved through the helicase 
action of BLM in conjunction with the topoisomerase TOP3α 132, the resulting
product will be a non-crossover and innocuous to the cell (Figure 1.2A). 
However, if the dHJ is processed through resolvases such as the heterodimer 
Mus81-Eme or GEN1, the resulting outcome can be a crossover 133-135 (Figure 
1.2B), which could have deleterious consequences at the telomere. 
Due to the repetitive nature of telomeric DNA, strand invasion could take 
place at any point along the telomere and if the crossover results in an unequal 
exchange, the outcome is one lengthened telomere and one shortened telomere. 
This becomes problematic for the daughter cell that inherits the shorter telomere 
that can be dysfunctional or limit the replicative potential of the cell. These 
crossover events can be detected at dysfunctional telomeres by an assay called 
CO-FISH and are called telomeric-sister chromatid exchanges (T-SCEs) 136
(Figure 1.3). Unbridled HDR at the telomere is an alternative method (ALT, 
Alternative lengthening of telomeres) for telomere maintenance in the absence of 
telomerase (reviewed in 137). ALT has been observed both in in vitro immortalized 
human cells and in a subset of human cancers 138,139, further illustrating the need 
for repression of HDR at the telomere. Alternatively, a process termed break 
induced replication (BIR) occurs when only one DSB is available for repair, for 
which the end of the telomere may be a likely substrate (Figure 1.2D). After 
strand invasion DNA synthesis may occur using the migrating D loop as a 
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template 140,141, recently referred to as bubble migration 142,143, with fill-in 
synthesis replicating the lagging strand. This process could potentially continue 
along for the length of the chromatid. In this case, while the danger of unequal T-
SCEs is not preeminent, BIR could cause excessive lengthening of telomeres 
and affect the normal telomere-driven senescence program 144. 
Another threat to telomeres includes their susceptibility to undergo 
excessive resection of their 5’ end during the process of overhang generation. 
While telomeric overhangs naturally occur during lagging strand synthesis, 
leading ends would presumably require additional processing for overhang 
formation 145. Telomeres require the 3’ overhang both for protection from DNA 
repair and to create a substrate for telomerase, yet this process must be carefully 
controlled and inhibit excessive nucelolytic degradation.  
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Figure 1.2 Homology-directed repair. Schematic illustrating processing steps in homology 
directed repair and potential outcomes. (A) Non-crossover products occur when double Holliday 
junctions (dHJ) are dissolved. (B) Both non-crossovers and crossovers can be the result dHJ 
resolution by nucleases. Non-crossovers can be detected by the CO-FISH assay (Figure 1.3A). 
(C) Break-induced replication is an alternate form of repair that can occur when only one DSB is 
available for repair, for example the telomere. 
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Figure 1.3 CO-FISH detects T-SCEs. Adapted from 154. (A) Chromosome orientation 
fluorescence in situ hybridization (CO-FISH) is a method that can detect HDR events at the 
telomere that have been resolved as crossovers. Briefly, cells are incubated with BrdU and BrdC 
for one round of replication. Metaphases are then harvested and treated with UV to generate 
nicks in the newly synthesized strand due to BrdU/C sensitivity. This strand is then digested with 
Exonuclease III, leaving the parental DNA strands intact. Due to the G-rich and C-rich nature of 
complementary strands of telomeric DNA, exchange of sequence between sisters can be 
detected by hybridization and colocalization of fluorescent G-rich and C-rich probes. (B) 
Schematic showing telomere-sister chromatid exchanges (T-SCEs). An equal exchange would be 
innocuous, however an unequal exchange could be deleterious to the daughter cell that inherits 
the shortened telomere. 
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1.2.4 Shelterin solves the end-protection problem 
Genetically engineered conditional mouse knockouts have revealed that 
shelterin components are essential (with an exception discussed in chapter 2) 
and disable threats to telomere integrity in a compartmentalized manner (Figure 
1.4). TRF2 is responsible for inhibiting ATM activation and subsequent repair by 
NHEJ 24. TRF2 is thought to repress ATM activation and NHEJ by facilitating 
formation of a t-loop, where the 3’ overhang strand invades into the telomere 
duplex, thereby ‘hiding’ the end from the MRN complex and blocking the loading 
of Ku70/80 146,147. POT1 represses activation of the ATR kinase at telomeres 
31,148. Deletion of TIN2 and TPP1 in MEFs phenocopies the POT1a/b double 
knockout, thus revealing recruitment of POT1 to the telomere as the primary 
function of these two components 83,149-151. POT1 is proposed to repress ATR 
activation by excluding RPA from binding to the single-stranded overhang 
148,152,153. TRF2 and POT1a/b also appear to prevent HDR since they repress the 
formation of T-SCEs when Ku70 is also absent 154,155. However, the mechanism 
for shelterin-mediated repression of T-SCEs is unclear. 
In contrast to the other shelterin components, TRF1 does not appear to 
play a critical role in protecting telomeres from DNA damage signaling and repair. 
Deletion of TRF1 resulted in activation of ATR signaling during progression of S-
phase and in the appearance of fragile telomeres in metaphase spreads. These 
phenotypes were ascribed to the increase in replication fork-stalling when TRF1 
was removed from telomeres 156,157. DNA helicases BLM and RTEL1 also 
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facilitate replication of the telomere, presumably by removing G quartets that may 
form due to the G-rich sequence of telomeric DNA 156,158,159. 
Removal of the entire shelterin complex from mouse telomeres resulting in 
shelterin-free telomeres  revealed that chromosome ends are vulnerable to fusion 
even when canonical components of the c-NHEJ pathway, Ku80 and Lig4, are 
absent 120. These fusions events are mediated by PARP1 and Lig3 dependent 
alt-NHEJ 120,121. Detection of HDR in shelterin-free Ku80 deficient cells was not 
possible due to high levels of telomere fusions, however T-SCEs were observed 
in shelterin-free Lig4- and 53BP1- deficient cells. Additionally, when shelterin was 
deleted from 53BP1-deficient cells, telomeres underwent extensive nucleolytic 
degradation 120. Thus, HDR, alt-NHEJ and 5’ end resection are threats to 
telomeres that are thwarted redundantly by general repressors and multiple 
components of shelterin. 
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Figure 1.4 Shelterin solves the end-protection problem. Shelterin components are required to 
inhibit DNA damage signaling and repair at chromosome ends. Ku70/80 and 53BP1 acts as 
general repressors of HDR and resection respectively, but how they perform their dual function in 
telomere protection and promoting DNA repair is not yet understood. 
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1.2.5 Phenotypes of TRF2 depletion 
Deletion of TRF2 from SV40-immortalized mouse embryonic fibroblasts 
(MEFs) led to the concomitant depletion of Rap1 protein from the telomere and 
the cell 24. Removal of TRF2 using dominant negative alleles also results in 
diminished levels of Rap1 160. Consequently, analysis of phenotypes associated 
with loss of TRF2 could be due to either TRF2, or Rap1, or both. My aims 
(discussed in section 1.4) were to understand the contributions to and 
mechanisms of telomere protection endowed by Rap1.  
Expression of dominant negative alleles of TRF2 in human cells or 
deletion of TRF2 in MEFs leads to activation specifically of the ATM kinase 24,148. 
This signaling can be quantified by the appearance and localization of DNA 
repair factors and modifications such as 53BP1 and γH2AX, respectively, to 
majority of the telomeres, referred to as TIFs (telomere dysfunction-induced foci) 
108. Depletion of TRF2 also results in phosphorylation of Chk2, activation of p53 
and apoptosis, consistent with ATM activation 161. Massive induction of telomere-
telomere fusions was also observed on metaphase spreads from cells lacking 
TRF2. These fusions primarily occurred in G1 162 and were mediated by c-NHEJ 
as revealed by their dependency on the presence of Ku70 and Lig4 24,154. The 
fusion of dysfunctional telomeres is promoted by 53BP1-mediated mobility of 
telomeres 163,164 and inhibition of resection 165. ATM deficiency abolishes both TIF 
formation and telomere fusions upon deletion of TRF2, establishing that DNA 
damage signaling is required for NHEJ-mediated DNA repair to occur 148. In 
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addition, deletion of TRF2 in the context of Mre11 or Nbs1 deficiency also 
diminishes formation of TIFs and fusions indicating that MRN is required for ATM 
activation at dysfunctional telomeres, as it is at DSBs 166-168. TRF2 protects 
telomeres from detection by ATM and repair by NHEJ by sequestering the 
overhang in a t-loop, visualized by electron microscopy and STORM imaging 
147,169. T-loop formation is thought to conceal the DNA end, thereby preventing 
binding of MRN or Ku70/80. In addition, ATM inhibition at linear telomeres not in 
the t-loop configuration may be mediated by the so-called iDDR, a 25 amino acid 
stretch (aa 407-431) in TRF2 that inhibits the E3 ubiquitin ligase RNF168, 
preventing accumulation of 53BP1 at telomeres 170. 
Loss of TRF2 in Ku70-deficient MEFs leads to induction of HDR, 
visualized by the appearance of T-SCEs 154, indicating that TRF2 plays a role in 
repressing HDR. The Ku70/80 heterodimer, which is known to repress HDR at 
DSBs 171, represses HDR at telomeres independently of shelterin. The 
mechanism by which TRF2 represses HDR is not known. 
A third function of TRF2 is the inhibition of t-loop cleavage where the t-
loop is excised as an extrachromosomal circle and loss of telomeric DNA from 
chromosome ends is detectable on metaphase spreads and genomic blots 172. 
The ability of TRF2 to prevent t-loop cleavage and its associated stochastic 
telomere losses is dependent on its N-terminal basic domain 172. Biochemical 
experiments have shown that the basic domain of TRF2 can bind and stabilize 
Holliday Junctions (HJs), which would be expected to form at the base of the t-
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loop when branch migration takes place 173,174. Expression of a TRF2 mutant 
lacking the basic domain (TRF2ΔB) was able to repress NHEJ but stochastic 
events of t-loop cleavage were observed 172. T-loop cleavage was diminished in 
TRF2ΔB-expressing cells when levels of HJ resolvases Mus81 and Gen1 were 
reduced by shRNAs 175, suggesting TRF2 restrains the action of these HDR-
associated nucleases. Expression of TRF2ΔB in TRF2 and Ku70 null cells does 
not however induce T-SCEs 154, revealing that TRF2 represses t-loop cleavage 
by HJ resolvases and HDR-mediated formation of T-SCEs through different 
mechanisms.   
1.2.6 Phenotypes of POT1 depletion 
ATR signaling at telomeres is repressed by the ssDNA binding protein 
POT1 148. Depletion of mouse POT1a results in a TIF response 31,32 that is 
exacerbated upon co-deletion of POT1b, however POT1b null MEFs alone 
exhibit no TIFs 31. Deletion of POT1b, but not POT1a results in extended single-
stranded overhangs 31 indicating that POT1a and POT1b have evolved to 
perform different functions of telomere protection. An RPA exclusion model has 
been proposed to explain POT1 inhibition of ATR activation 148,152, where POT1a 
prevents RPA from binding to the overhang 153. RPA is substantially more 
abundant than the TPP1/POT1 heterodimer and binds single-stranded telomeric 
DNA with similar affinity, but the tethering of TPP1/POT1 to the rest of shelterin 
by TIN2 is proposed to give POT1 the ability to outcompete RPA 149,176.  
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The mechanism by which POT1b maintains telomere overhangs of correct 
length involves the recruitment of the CST complex to presumably perform fill-in 
synthesis of the C-rich strand. Leading- and lagging- strand overhangs are 
generated through different mechanisms, where leading-ends require initial 
processing by the Apollo/SNM1B nuclease 177,178 that is recruited by TRF2 
27,179,180. POT1b is required to prevent hyper-resection of both leading and 
lagging ends by Apollo. Leading and lagging ends are however both extensively 
resected by Exo1 during S/G2 181 in the presence of POT1b 52. POT1b is then 
responsible for recruiting the CST complex that restores overhangs to their 
normal length 52.  
Few chromosomal abnormalities are noted upon loss of POT1a/b, which 
include a low level of telomere fusions that occur in G2, and sister telomere 
‘associations’, although the molecular basis of this phenotype is unclear 31,182. 
The sustained DNA damage induced by POT1a/b deletion leads to 
endoreduplication and eventually growth arrest 31,183. Deletion of both POT1a/b in 
Ku70 deficient cells leads to an induction of T-SCEs 155, indicating that either 
POT1a or POT1b is sufficient to inhibit HDR.   
Human POT1 has two isoforms, POT1-FL (full-length) and POT1-55, 
which lacks the first of the two OB-folds 184. No function has been reported for 
POT1-55. Depletion of human POT1 with shRNAs results in transient DDR 
activation 184, a slight reduction in overhang signals and growth arrest in primary 
cells 185 but not transformed cells 184. Another feature of POT1 depletion from 
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human cells is loss of specificity of the 5’ end. Greater than 80% of normal 
telomere ends have been reported to end in ATC-5’ on the C-rich strand, while 
there appears to be less selectivity for terminal nucleotides on the G-rich 
strand186. Depletion of human POT1 abrogated sequence precision of the 5’ end 
184. It remains to be seen whether the telomere maintenance mechanisms of 
human POT1 resemble those of mouse POT1a and PO1b. 
1.3 Proposed functions and mechanisms of action for Rap1 
1.3.1 Identification of Rap1 
Rap1 was first purified and cloned from S. cerevisiae as a transcriptional 
regulator and thus named repressor/activator binding protein 1 187. 
Transcriptional regulation by scRap1 arises from its ability to bind directly to 
specific DNA sequences located in several promoter regions including ribosomal 
genes, as well as at silencer elements. The activation and silencing domains of 
scRap1 have been mapped to the C-terminus of Rap1 188. The silent information 
regulators Sir3p and Sir4p bind to this C-terminal region of Rap1 and function in 
sub-telomeric silencing of genes adjacent to telomeres 189,190. Gene disruption of 
Rap1 in S. cerevisiae results in lethality, which was proposed to be due to its 
function in activation of ribosomal gene loci 187. Further investigation revealed 
that Rap1 binds directly to telomeric DNA 40-42 and the requirement of Rap1 for 
viability was attributed to its role in telomere protection 191. 
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Initially identified in a yeast two-hybrid screen with human TRF2, 
mammalian Rap1 was found to be a distant ortholog of scRap1 20. Although the 
sequence conservation is extremely low (too low for a simple BLAST search), the 
two Rap1 proteins have a similar domain structure featuring a single N-terminal 
BRCT domain, a central region with homology to the Myb DNA binding domain, 
and a Rap1-specific C-terminal (RCT) protein-interaction domain (Figure 1.5). 
However, unlike budding yeast Rap1, which recognizes telomeric DNA directly 
through the cooperation of its Myb domain with a second motif that forms a Myb-
like fold 41,192, mammalian Rap1 associates with telomeres solely through its 
interaction with TRF2 20. The Myb domain of mammalian Rap1 is not suited for 
DNA binding because its surface lacks positive charge and therefore is more 
likely to bind to a protein 193. The targets of the single BRCT domain in the Rap1 
proteins are not known. In other proteins, BRCT domains usually occur as 
tandem pairs and can function as a phosphopeptide binding module 194.  
1.3.2 Rap1 and telomere length regulation 
Telomere length regulation by Rap1 in budding yeast is conducted through 
its interaction with Rif1 and Rif2 (Rap1 interacting factor 1 and 2), as evidenced 
by the elongation of telomeres in their absence 195,196. A proposed mechanism of 
Rif1 and Rif2 action in the negative regulation of telomere length is by interfering 
with recruitment of Tel1 (the ATM ortholog). The MRX (Mre11-Rad50-Xrs2) 
complex binds to telomeres in S. cerevisiae and recruits Tel1197,198. Tel1 has 
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been shown to preferentially associate with short telomeres 199-201 and facilitate 
their elongation. Rap1 binding partners Rif1 and Rif2 are proposed to compete 
with Tel1 binding to the MRX complex, hence preventing the subsequent steps 
that allow for telomerase recruitment 202. Additionally, while S. pombe Rif1 does 
not bind directly to Rap1, it localizes to the telomere and is involved in regulating 
telomere length 36. Although a mammalian ortholog of Rif1 (not Rif2) has been 
identified, it does not localize to functional telomeres, nor is it involved in 
telomere length homeostasis 203. Instead Rif1 localizes to DSBs and 
dysfunctional telomeres and promotes NHEJ by inhibiting resection downstream 
of 53BP1 165,204-207. Additionally Rif1 also participates in the intra-S phase 
checkpoint, responding to replication stress 203,208, and timing of replication origin 
firing 209,210. Thus it seems unlikely that hRap1 follows the budding yeast Rap1 
paradigm in using Rif1 to maintain telomere length homeostasis. 
1.3.3 Rap1 and end-protection 
In both S. cerevisiae and S. pombe, Rap1 is required for the prevention of 
NHEJ at chromosome ends 191,211. Some mechanistic insight has been obtained 
from studies in S. cerevisiae that indicate Rap1 can protect telomeres from fusion 
via its C-terminal interactors Rif2 and Sir4, and also by its central domain (which 
includes the DNA binding domain) 212. Despite not binding to telomeric DNA, 
Rap1 in S. pombe has also been shown to inhibit telomere fusions 211. While 
mammalian orthologs of Sir4 and Rif2 do not exist, deletion of TRF2 and Rap1 
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from MEFs resulted in telomere fusions, suggesting mammalian Rap1 may have 
retained its function in repressing NHEJ 24. Furthermore, human Rap1 can block 
NHEJ when it binds to TRF2 loaded on a telomeric end-joining substrate in vitro 
213, and a Rap1-fusion protein can reduce telomere fusions when it is tethered to 
telomeres that are depleted of TRF2 160. 
In several species of budding yeast, namely Kluyveromyces lactis (kl) and 
Candida albicans (ca), Rap1 functions in repressing homologous recombination 
at the telomere. The K. lactis strain ter1-16T expresses a re-programmed 
telomerase that synthesizes telomeres lacking Rap1 binding sites, leading to 
elongated telomeres with an especially long 3’ overhang. Electron microscopy of 
these cells revealed the formation of T-loop structures and an abundance of t-
circles. When Rad52, a bona fide HDR component in budding yeast was absent, 
the incidence of t-circles decreased indicating that the t-circles were products of 
HDR, suggesting Rap1 binding to telomeres is required to inhibit recombination 
214. Complete deletion of caRap1 also exhibited an abundance of t-circles in 
comparison to wild type 215. Depletion of TRF2 and Rap1 from Ku70 null cells 
resulted in T-SCEs, raising the possibility that mammalian Rap1 may also be 





Figure 1.5 Mammalian Rap1 resembles yeast and trypanosome Rap1. Adapted from 227. 
Schematic representation of conserved protein motifs of Rap1 and its TRF2-like partners in the 
indicated organisms. Amino acid positions indicated in schematic of mammalian Rap1 
correspond to mouse Rap1. MYB indicates regions with a MYB sequence. MYB-fold indicates a 
motif that lacks sequence similarity to the MYB sequence but has a similar fold. MYB-like 
indicates sequence similarlity to the MYB-fold of S. cerevisiae, but their structure has not been 
determined. S. cerevisiae interacts with several factors important for its functions via its RCT 
domain. “RCT” of S. pombe indicates the region of Rap1 that is required for interaction with Taz1. 
It is not known whether T. brucei has a RCT domain, but the C-terminus of tbRap1 is not required 
for interaction with its TRF interacting partner.   
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1.3.4 A role for Rap1 in meiosis and chromatin organization 
Telomeres are involved in chromatin reorganization during meiosis in 
yeasts, worms and mammals. During meiotic prophase I, telomeres attach to the 
nuclear envelope mediated by SUN/KASH-domain nuclear transmembrane 
complexes and other meiosis-specific protein complexes (reviewed in 216). 
Following leptotene, telomeres cluster around the centrosome resulting in 
bouquet formation, proposed to stimulate homologous chromosome pairing and 
meiotic recombination. Rap1 in fission yeast is necessary for telomere clustering 
at the spindle pole body during the premeiotic horsetail stage, which in mammals 
is analogous to bouquet formation in meiosis 36,217,218. During normal cell division, 
telomeres are tethered to the nuclear envelope during the process of nuclear 
assembly, potentially mediated by an interaction between Rap1 and SUN1 219.  
1.3.5 Non-telomeric functions of mammalian Rap1 
Transcriptional regulation by Rap1 has been demonstrated in budding 
yeast as well in trypanosomes. Similar to budding yeast tbRap1 largely localizes 
to the telomere, but not exclusively. T. brucei normally express one variant 
surface glycoprotein (VSG) from subtelomeric loci in a monoallelic fashion. 
Knockdown of tbRap1 led to derepression of VSG expression sites causing 
simultaneous expression of multiple different VSGs 39.  
Unlike in S. cerevisiae, where Rap1 interacts with sirtuins (Sir3p and 
Sir4p) that regulate transcription, mammalian Rap1 does not interact with the 
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sirtuins, however it has been shown to localize to over 30,000 chromosome-
internal sites and control gene expression, affecting metabolism and body weight 
control 220-223. ChIP-seq for Rap1 in MEFs indicated that it predominantly 
localized to chromosome internal loci with [TTAGGG]2 as a consensus motif, 
suggesting TRF2-mediated recruitment to these sites. Rap1 was also detected at 
telomere sequences containing a mismatch that disrupts TRF2 binding, 
suggesting additional interacting partners and modes of recruitment for Rap1 220. 
Indeed, regulation of metabolic genes by Rap1 was independent of its ability to 
bind TRF2 221. Human Rap1 has also been reported to associate with 
chromosome internal loci, but the number of sites (~100) is much lower 223. 
Another unanticipated function of Rap1 is its role in the modulation of 
NFκβ signaling. Rap1 was identified in a gain-of-function screen for regulators of 
NFκβ 224. Despite the predominantly telomeric localization of Rap1, the authors
observed a cytoplasmic fraction of Rap1 that is constitutively associated with Iκβ 
kinases (IKKs). IKKs are responsible for phosphorylation and subsequent 
degradation of inhibitors of NFκβ (Iκβ proteins). They found that Rap1 requires 
interaction with IKKs to activate NFκβ gene expression and suggested that Rap1 
directs IKK activity specifically to p65, an inhibitory subunit of NFκβ. These 
results are surprising when taking into account data that shows that very little 
Rap1 is not bound to TRF2 19, however it is possible that Rap1 has other 
interacting factors that recruit it to the cytoplasm, or Rap1 shuttles back and forth 
from the nucleus to the cytoplasm. Numerous Rap1-interacting factors have been 
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identified by mass spectrometry and proximity-based YFP fluorescence 
complementation screens, yet none of these interactions have been carefully 
characterized and it is unclear what roles they may play in protection and 
maintenance of telomeres 78,225,226.  
1.4 Objectives 
The first objective of this thesis was to understand the role of Rap1 in 
telomere end-protection. This was carried out using two independent methods: 
generation of a Rap1 conditional mouse knockout and analysis of a TRF2 mutant 
defective in Rap1 binding. These two approaches revealed that mouse Rap1 was 
required to inhibit HDR, but not NHEJ at the telomere. 
The second objective, stemming from the discovery that Rap1 represses 
telomeric HDR, was to investigate the mechanism of this inhibition. Examination 
of a panel of Rap1 mutants indicated that the C-terminus of Rap1 was required to 
inhibit HDR. Further analysis suggested that Rap1 needs to be bound to TRF2 in 
order to repress HDR, although the mechanism by which Rap1/TRF2 act remains 
to be elucidated. 
The third objective, facilitated by the development of efficient genome-
editing technologies in human cells, was to query the discrepancy between the 
claimed functions of mouse and human Rap1. In contrast to mouse Rap1, in vitro 
and in vivo data had implicated human Rap1 in shielding telomeres from NHEJ. 
In addition, no deregulation of telomere length was noted in mouse cells lacking 
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Rap1, whereas human Rap1 had been implicated in telomere length 
homeostasis. To determine whether human Rap1 protects telomeres from NHEJ 
and negatively regulates telomere length, Rap1 knockouts were generated in a 
panel of human cell lines.  
The fourth and final objective of this thesis was to construct human 
knockouts of POT1 to investigate its functions in and mechanisms of telomere 
protection, and to compare the role of human POT1 to those of mouse POT1a 
and POT1b.  
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Chapter 2: Loss of Rap1 Induces Telomere Recombination 
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2.1 Introduction 
Previous loss-of-function studies that removed TRF2 from the telomere 
also noted concomitant loss of Rap1 24,160. Rap1 may therefore play a role in 
functions ascribed to TRF2, namely repression of the ATM kinase and inhibition 
of the DSB repair pathways, NHEJ and HDR 24,148,154,161. In addition, 
overexpression and partial knockdown experiments revealed Rap1 as a potential 
regulator of telomere length 23,78. In order to understand the contribution(s) of 
mammalian Rap1 to telomere protection two strategies were devised to remove 
Rap1 from the telomere and study the phenotypes of its loss. The two 
approaches taken were to 1) make a conditional mouse knockout of Rap1 and 2) 
to capitalize on the dependency of Rap1 on its telomeric recruitment by TRF2, by 
generating a TRF2-separation-of-function mutant that could fulfill all functions of 
TRF2 except interacting with Rap1. The results of these studies are reported 
here.  
2.2 Results  
2.2.1 Deletion of Rap1 does not affect cell and organismal viability 
The gene for the mouse Rap1 protein is annotated as TERF2IP (telomeric 
repeat binding factor 2 interacting protein) but referred to as Rap1 henceforth. 
Because the first exon of Rap1 immediately abuts the essential KARS lysyl-
tRNA-synthetase gene, a conditional knockout strategy was developed where a 
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Rap1 floxed (Rap1F) allele was created by flanking exon 2 with LoxP sites (Agnel 
Sfeir, Figure 2.1A-C). Deletion of exon 2 by retroviral expression of Cre 
recombinase results in a premature stop codon in exon 3. The C-terminus of 
Rap1 is encoded by exon 3 and is required for its interaction with TRF2 and 
recruitment to the telomere. The resulting Rap1Δex2 allele can potentially encode 
a fragment containing the N-terminus of Rap1 (Agnel Sfeir, Figure 2.1A). 
Exogenous expression of FLAG-tagged Rap1-ex1 (exon1) showed that this 
truncated form of Rap1, if it were produced, would not bind or localize to 
telomeres (Agnel Sfeir, Figure 2.1D-F). Indirect immunofluorescence (IF) on 
samples where nucleoplasmic proteins had been removed by treatment with 
Triton-X showed no visible signal of FLAG Rap1-ex1 (Agnel Sfeir, Figure 2.1E). 
Similarly, fractionation of cells expressing FLAG Rap1-ex1 showed that the 
protein was largely cytoplasmic and could not be detected in the chromatin 
bound fraction (Agnel Sfeir, Figure 2.1F). 
Rap1F/F MEFs were isolated at embryonic day 13.5 and immortalized with 
SV40 large T antigen (SV40LT). IF and immunoblotting showed that Cre-treated 
SV40LT-immortalized Rap1F/F MEFs indeed lacked any detectable full-length or 
truncated Rap1 protein (Agnel Sfeir, Figure 2.2A-C) and chromatin 
immunoprecipitation (ChIP) showed the loss of Rap1 from telomeres. The 
expression and localization of other shelterin components were not significantly 
affected (Agnel Sfeir, Figure 2.2D).   
 37 
.  
Figure 2.1 Strategy to conditionally delete mouse Rap1. (A) Schematic of Rap1, the mouse 
Rap1 (TERF2IP) locus, the targeting construct, the floxed allele, and the Δex2 allele. N, NdeI; B, 
BamHI; F1, F2, and R, PCR primers. Rap1 shRNAs shown at the bottom. At right, Rap1Δex2-
encoded protein. (B) Genomic blot of NdeI-digested DNA from ES cells. Probe in (A). (C) 
Genotyping of tail DNAs. Primers in (A). (D) Immunoblot for Rap1 in cells expressing FLAG FL-
Rap1, FLAG Rap1-ex1, or vector control. The schematic below depicts full-length Rap1 protein 
(FLAG FL-Rap1) and the protein fragment encoded by exon 1 (FLAG Rap1-ex1). The antigenic 
region recognized by Rap1 Ab 1252 is indicated. (E) IF to monitor the localization of FLAG Rap1-
ex1 and FLAG FL-Rap1. Rap1Δex2/Δex2 MEFs expressing FLAG Rap1-ex1 or FLAG FL-Rap1 are 
stained with FLAG (green) and TRF1 (red). (F) Rap1Δex2/Δex2 MEFs expressing FLAG Rap1-ex1, 
FLAG FL-Rap1 or vector control were fractionated as described in the materials and methods 
section and equal fractions of cytoplasmic proteins (CP), nucleoplasmic proteins (NP), and 







Figure 2.2 Deletion of Rap1 does not affect localization of other shelterin components to 
telomeres. (A) Loss of Rap1 IF signal from Cre-treated (day 5) Rap1F/F MEFs. Red, Rap1; 
green, telomeric FISH; blue, DNA (DAPI). (B) Western blot showing the disappearance of full- 
length Rap1 in cells deleted for exon 2. No new Rap1 protein was detected in cells bearing the 
Rap1Δex2 allele. (C) Immunoblots for Rap1 (Ab1252), TRF2 (Ab1254), and TRF1 (Ab1449) from 
Rap1F/F and Rap1F/+ MEFs five days after Hit&Run-Cre (first lane) or pWZL-Cre (second lane). 
(D) Telomeric ChIPs on Cre-treated (day 5) Rap1F/F MEFs. Numbers represent ratios of % 
telomeric DNA in the ChIPs (pre-immune (PI) signal subtracted) on cells + and -Cre. 
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The growth rate of the SV40LT immortalized Rap1Δex2/Δex2 MEFs was 
similar to control cells, and primary MEFs lacking wild type Rap1 did not show a 
growth arrest or p53 activation  (Agnel Sfeir, Figure 2.3A-C). Furthermore, 
Rap1Δex2/Δex2 mice were born at the expected frequencies and were fertile (Agnel 
Sfeir, Figure 2.3D). The survival of Rap1Δex2/Δex2 cells and mice argues that Rap1 
deletion does not result in major telomere dysfunction, which is known to be 
lethal. While there was no evidence of translation of the truncated N-terminus of 
Rap1, to conclusively determine that no telomere-protection was being afforded 
by this fragment, Rap1Δex2/Δex2 MEFs were infected with an shRNA targeting exon 
1 (Agnel Sfeir, Figure 2.3E). Treatment with the shRNA targeting exon 1 did not 
induce a growth arrest or other phenotypes typical of telomere dysfunction further 
validating the previous conclusions. 
In the second approach to remove Rap1 from telomeres, previously 
characterized TRF2F/-p53-/- MEFs were used 24 to replace the endogenous TRF2 
with a mutant that does not bind to Rap1. A short predicted helix at position 290 
in the previously mapped Rap1 binding region (aa 260-360; 20) was conserved in 
TRF2 orthologs but not in TRF1 (Figure 2.4A-B). Two mutations in this region 
(A289S and F290S) reduced the interaction between Rap1 and TRF2 in co-IP 
experiments (Giulia Celli, Figure 2.4C). To generate TRF2ΔRap1, aa 284-297 were 
deleted  (Megan van Overbeek, Figure 2.4D). TRF2ΔRap1 failed to bind to Rap1 in 
co-IP experiments whereas it retained its previously reported interaction with 
Apollo (Megan van Overbeek, Figure 2.4E). TRF2ΔRap1 was expressed in TRF2F/-
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p53-/- MEFs and the endogenous TRF2 was removed with Cre, resulting in 
depleted Rap1 protein levels (Megan van Overbeek, Figure 2.4F). Although 
TRF2ΔRap1 localized to telomeres efficiently, IF and ChIP indicated that the 
telomeres lacked Rap1 (Figure 2.5A-B). Other shelterin components were 
affected to an extent (<2-fold; Figure 2.5B) that is not expected to be functionally 
significant as heterozygous MEFs and mice lacking one copy of TRF1, TPP1, 
TRF2, or POT1a/b display no telomere defect. Assessment of shelterin 
occupancy at telomeres by ChIP displayed some variability due to antibody 
quality and inexact experimental processing (Figure 2.5B). Despite this variability, 
on average less than 10% of residual Rap1 remained at telomeres in TRF2 null 
MEFs complemented with TRF2ΔRap1, while levels of other shelterin components 
in these cells were approximately 85% or higher, compared to cells 
complemented with wild type TRF2 (Figure 2.5B). Consistent with the viability of 
Rap1Δex2/Δex2 cells, cells expressing TRF2ΔRap1 proliferated at the same rate as 
cells expressing wild type TRF2 (Megan van Overbeek, Figure 2.5C-D).  
2.2.2 No induction of DDR or NHEJ at telomeres lacking Rap1 
Rap1Δex2/Δex2 cells did not show TIFs and phosphorylation of Chk1 and 
Chk2 (Chk1-P, Chk2-P) was not evident (Figure 2.6A-C). Further depletion of 
Rap1 mRNA with an shRNA also failed to elicit a DNA damage signal in 
Rap1Δex2/Δex2 cells (Figure 2.6B). Consistent with these results, TRF2ΔRap1 was 
equivalent to wild type TRF2 in its ability to repress TIFs in cells lacking 
 41 
endogenous TRF2 (Figure 2.6D-F). The mutant form of TRF2 also repressed the 
induction of Chk2-P to the same extent as wild type TRF2 (Figure 2.6E). The low 
level of Chk2-P observed in Cre-treated TRF2- and TRF2ΔRap1- expressing cells 
is likely due to Cre-induced DNA damage, since the phosphorylation of Chk2 was 
diminished when using a version of Cre (Hit&Run) that eventually disappears 
from the cells due to self-deletion (Figure 2.6F).  
Telomere fusions were not induced by deletion of Rap1 and TRF2ΔRap1 
had the same ability as wild type TRF2 to repress NHEJ at telomeres (Figure 
2.7A-C). However, as previously discussed, NHEJ of telomeres lacking TRF2 
requires active DNA damage signaling 148 thus the lack of telomere fusions could 
be due to the lack of ATM/ATR activation. In order to initiate DNA damage 
signaling specifically at the telomere, we used a TPP1 shRNA to activate the 
ATR kinase. This approach previously resulted in the reactivation of NHEJ at 
telomeres of TRF2- and ATM-deficient cells 148. Despite ATR kinase signaling at 
telomeres and induction of TIFs elicited by the TPP1 shRNA (Figure 2.6B,D), 
Rap1 removal from telomeres did not induce their fusion (Figure 2.7B-C). Thus, 
Rap1 does not appear to be required in either the repression of NHEJ or ATM 







Figure 2.3 Rap1 deletion does not affect cell and organismal viability. (A) Proliferation of 
SV40LT-immortalized Rap1F/F and Rap1F/+ MEFs infected as indicated. (B) FACS profiles of 
primary Rap1F/F cells infected with pWZL-Cre (left panel) or vector control (right panel), analyzed 
at day 5 after infection. The percentage of G1, S and G2 cells is noted within the FACS profile. 
(C) Immunoblot for Rap1 on MEFs with the indicated genotype, 96 hours after Cre treatment. (D) 
Offspring from Rap1∆ex2/+ and Rap1∆ex2/∆ex2 intercrosses. (E) Western blot showing the effect of 
Rap1 shRNAs 1 and 2 on Rap1 levels in wild type MEFs. 





Figure 2.4 A TRF2 mutant deficient for Rap1 binding. (A) Schematic of TRF2 showing 
conservation of a subset of amino acids within the previously mapped Rap1 interaction domain. 
(B) Identification of a helical region within the conserved segment. Predicted protein structure 
from PredictProtein.org. (C) Co-IPs of FLAG-tagged Rap1 with wild type TRF2, TRF2 mutants or 
no protein. (D) The TRF2∆Rap1 mutant. H, predicted helix. (E) Co-IP of Myc-TRF2 or Myc-
TRF2∆Rap1 with FLAG-Rap1 or FLAG-Apollo from co-transfected 293T cells. In, 2.5% of input. (E) 
Immunoblots for TRF2 and Rap1 from TRF2F/-p53-/- MEFs expressing the indicated alleles at 72 
and 96 hours after Hit&Run-Cre. 




Figure 2.5 TRF2ΔRap1 expression results in diminished levels of Rap1. (A) IF-FISH to monitor 
TRF2, Rap1, and TIN2 at telomeres in TRF2F/-p53-/- MEFs expressing TRF2∆Rap1 or vector control 
at day 4 after Cre. (B) Telomeric ChIP of TRF2F/-p53-/- MEFs expressing TRF2 or TRF2∆Rap1 at 
day 4 post Cre. Duplicate dot blots were probed for telomeric DNA or the dispersed BamHI 
repeats. ChIP ratios represent the % telomeric DNA recovered in TRF2∆Rap1 vs. TRF2 expressing 
cells. ChIP ratios are shown from two independent experiments and averages with SEMs are 
listed to the right. (C) Immunoblots showing the expression of Rap1, TRF2, and TRF2∆Rap1 in 
TRF2F/-p53-/- MEFs treated with pWZL-Cre for the indicated time-periods.  (D) Growth curve of 
cells shown in (C) and the vector controls. 
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Figure 2.6 No DNA damage signaling at telomeres lacking Rap1. (A) TIF assay on Rap1F/F 
MEFs treated with Cre and the indicated shRNA. Red, IF for 53BP1; green, telomeric FISH; blue, 
DNA (DAPI). (B) TIF assay quantification. Averages of two independent experiments (n≥100 
nuclei each) and SEMs. (C) Chk2-P in Rap1-deficient MEFs. TRF2 null cells and IR-treated cells 
(1 hr post 2 Gy,) serve as positive controls. (D) Quantification of TIF assays on TRF2F/-p53-/- 
cells expressing TRF2, TRF2∆Rap1 or vector control at day 4 post Cre. Mean of three 
independent experiments  (n≥100 nuclei each) and SDs. (E) Chk1 and Chk2 phosphorylation in 
TRF2F/-p53-/- MEFs expressing TRF2, TRF2∆Rap1 or vector control.  UV (1 hr post 25 J/m2) 
and IR (1 hr post 2 Gy) treated cells serve as positive controls. (F) Rap1 and Chk2 immunoblots 
of TRF2F/-p53-/- MEFs expressing TRF2, TRF2∆Rap1 or vector control, at 144 hours after 




Figure 2.7 Loss of Rap1 does not induce NHEJ. (A) Metaphase chromosomes from Rap1F/F 
cells 5 days post Cre. Red, false colored DNA DAPI stain; green, telomeric FISH. (B) 
Quantification of telomere fusions, detected as in (A) in Rap1F/F MEFs with the indicated Cre and 
shRNA treatments. Average % of telomeres fused is given. (C) Quantification of telomere fusions 
in TRF2F/-p53-/- MEFs (+ or – Cre, day 4) complemented with TRF2 or TRF2∆Rap1 or vector control 
and treated with TPP1 shRNA as indicated. 
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2.2.3 Telomere length and chromatin unchanged in Rap1-deficient cells  
To assess the role of Rap1 in telomere length regulation, telomere length 
was examined over three generations of mouse breeding and over approximately 
50 population doublings in cultured cells lacking Rap1 (Figure 2.8A-C). No overt 
changes in telomere length were detected. Furthermore, the amount of the 
single-stranded overhang remained unchanged in Rap1-deficient cells (Figure 
2.8D).  
Mammalian telomeres contain nucleosomes and epigenetic marks that are 
characteristic of heterochromatin, such as heavily methylated histones (reviewed 
in 228). Rap1 was not required for the maintenance of telomeric nucleosomal 
organization or the methylation of telomeric H3K9 (Agnel Sfeir, Figure 2.9A-C). In 
addition, the level of telomeric lncRNA called TERRA (telomeric repeat-
containing RNA; reviewed in 229) was not affected upon deletion of Rap1 (Agnel 
Sfeir, Figure 2.9D). 
2.2.4 Rap1 is a repressor of telomere recombination 
Homology-directed repair threatens telomere integrity because unequal 
telomere-sister chromatid exchanges can change telomere lengths. T-SCEs are 
most frequent when either TRF2 or POT1a/b are deleted from Ku-deficient cells 
154,155, although low levels of T-SCEs have been reported for POT1a deficiency 
alone 32. To determine whether Rap1 was required for TRF2-mediated repression 
of T-SCEs, TRF2ΔRap1 was introduced into SV40LT-immortalized TRF2F/-Ku70-/- 
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MEFs, which display frequent T-SCEs upon deletion of TRF2 with Cre. Whereas 
the telomeric exchanges were repressed by wild type TRF2, TRF2ΔRap1 failed to 
block the telomeric HDR (Fig. 2.10A-C). The frequency of T-SCEs was the same 
whether the cells expressed TRF2ΔRap1 or no TRF2 (Figure 2.10D). Furthermore, 
T-SCEs were induced by Cre-mediated deletion of Rap1 from Rap1F/FKu70-/- 
cells (Figure 2.10E). 
Notably, the T-SCEs occurred despite absence of TIFs in cells lacking 
both Ku70 and telomeric Rap1 (Figure 2.11A-B). Basal levels of Chk2-P were 
observed in cells lacking Rap1 and Ku70, but these were likely attributable to the 
Cre effect and Ku70 deficiency, as they were much lower than the induction of 
Chk2-P observed in the absence of TRF2 and Ku70 (Figure 2.11C-D). There 
appeared to be no effect on the terminal structure of telomeres in cells lacking 
Rap1 and Ku70 (Figure 2.11E).  
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Figure 2.8 Rap1 does not affect telomere length maintenance. (A) Telomeric restriction 
fragment analysis on cells isolated from the liver of a Rap1Δex2/+ mouse and three successive 
generations of Rap1Δex2/Δex2 mice. Telomeric DNA was detected by in-gel hybridization assays 
using a (CCCAAT)4 probe under denaturing conditions. (B) Telomere length analysis on 
Rap1Δex2/Δex2 MEFs and wild type cells at the indicated population doublings. (C) Telomere length 
analysis of TRF2F/- p53-/- cells expressing TRF2, TRF2ΔRap1, or vector, plus or minus treatment 
with Cre. (D) Loss of Rap1 does not alter the telomeric single-stranded DNA. MEFs with the 
indicated genotypes were analyzed at day 5 post Cre treatment using in-gel hybridization to MboI 
digested DNA. The panel on the left shows the hybridization signal using a (CCCAAT)4 probe 
under native conditions. The panel on the right represents total telomere signal after in situ 
denaturation of DNA and re-hybridization with the same probe. The numbers on the bottom 
represent the relative overhang signal normalized to the total telomeric repeat signal. Values of 
the normalized signal are compared between – Cre (set at 1) and +Cre samples. 







Figure 2.9 Telomeric chromatin and transcription unchanged upon Rap1 loss.  
(A) Unaltered nucleosomal organization of telomeric chromatin upon loss Rap1. DNA from 
MNase digested nuclei of Rap1F/F MEFs (+ or – Cre treatment) fractionated on a 1% agarose gel 
and stained with ethidium bromide (upper panel) to monitor organization of bulk nucleosomes or 
blotted and hybridized with a 32P-(CCCTAA)4 probe (lower panel). The two DNA samples marked 
by (*) were switched. The concentration of MNase ranged from 5 – 600 U/ml. (B) Rap1 loss has 
no effect on the heterochromatic marks at telomeres. Telomeric ChIP analysis of Rap1F/F cells 
treated with pWZL Cre or Hit&Run Cre as indicated. Antibodies used are indicated on top. Pre-
immune serum (PI) is used as a negative control. (C) Quantification of percentages of total 
telomeric DNA recovered in the ChIP shown in (B). (D) TERRA levels as detected by Northern 
blot analysis on Rap1 MEFs with the indicated genotype and Cre treatment. Ethidium bromide 
staining pattern serves as a loading control.  
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Figure 2.10 Rap1 is a repressor of telomere recombination.  (A) Rap1 and TRF2 from 
TRF2F/-Ku70-/- MEFs expressing TRF2, TRF2∆Rap1, or vector control analyzed 4 days after Cre.  
(B) CO-FISH analysis on cells in (A). Arrows: T-SCEs. (C) Enlarged T-SCE events in Cre-treated 
TRF2F/-Ku70-/- MEFs expressing TRF2∆Rap1. (D) Quantification of T-SCEs as assessed in (B). 
Bars represent averages from three independent experiments (n>1100 chromosome ends each) 
and SDs. P values based on Student’s two-tailed t-test. (E) Quantification of T-SCEs as assessed 
in (B) in cells of the indicated Rap1 and Ku70 status. Method as in (D). Errors bars: SEMs except 
for SDs for Rap1F/FKu70-/-. 
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Figure 2.11 T-SCEs observed in Rap1-deficient cells despite no DNA damage signaling.  
(A) TIF assay on TRF2F/- Ku70-/- SV40LT-immortalized MEFs expressing TRF2, TRF2∆Rap1 or 
vector control, before or after treatment with Cre. Red, IF for 53BP1; green, telomeric FISH; blue, 
DNA (DAPI). (B) Quantification of TIF assay in (A). (C) Immunoblots for indicated shelterin 
components, Chk1 and Chk2 of same cells as in (A). IR (1hr post 2Gy) and UV (1hr post 25 
J/m2) treated cells serve as positive controls. (D) Immunoblots for Rap1 and Chk2 on SV40LT 
immortalized MEFs with indicated genotypes, before and after treatment with Cre. γ-tubulin 
serves as loading control. (E) Loss of Rap1 in Ku-deficient SV40LT immortalized MEFs does not 
alter the telomeric single-stranded DNA. MEFs expressing TRF2, TRF2∆Rap1, or vector control 
were analyzed using in-gel hybridization to MboI digested DNA before and 96 hours after 
treatment with Cre. Left, hybridization signal with (CCCAAT)4 probe under native conditions; right, 
hybridization signal with same probe after denaturation. Overhang signal was normalized to the 
total telomeric repeat signal. Numbers represent the relative overhang signal as compared to 
TRF2 plus Cre (set as 1).  
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2.3 Summary of findings 
These data indicate that Rap1 functions at mouse telomeres to repress 
HDR, which has the potential for generating shortened telomeres and can 
promote telomerase-independent telomere maintenance. Furthermore, these 
results underscore the functional compartmentalization within shelterin where 
each subunit is dedicated to distinct functions. As previously reported, replication 
of telomeric DNA is facilitated by TRF1 156,157, TPP1/POT1 are required for the 
repression of ATR signaling 150,151, while TRF2 is the predominant repressor of 
both ATM signaling and NHEJ 24. The current data show that these functions of 
TRF2 do not require Rap1. Instead, Rap1 is required to repress HDR. 
Interestingly, this division of roles revealed that telomeres can undergo HDR 
without being detected by the ATM and ATR kinase pathways. When HDR takes 
place at telomeres lacking TRF2 or POT1a/b, DNA damage signaling results in 
the formation of TIFs. In the case of Rap1 removal, however, the telomeres lack 
detectable TIFs, yet are susceptible to HDR. Thus, the formation of DNA damage 
foci at telomeres is not a prerequisite for HDR. How exactly Rap1 represses HDR 
and the action of Ku in this repression remains to be determined.  
It is of interest to recall that expression of the TRF2ΔB mutant allele leads 
to stochastic t-loop loss, presumably because the basic domain of TRF2 
stabilizes Holliday Junctions and restrains the action of HJ resolvases 172-175. 
However, if the basic domain of TRF2 cannot inhibit HJ resolution, a critical step 
in the generation of T-SCEs, the question arises as to why T-SCEs are not 
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observed in TRF2ΔB-expressing TRF2/Ku70-deficient cells 154. One possibility is 
that Rap1 bound to TRF2 may repress the formation of HJs so that T-SCEs will 
not occur. For instance Rap1 and/or TRF2 may inhibit strand invasion into sister 
chromatids, or Rad51 filament assembly, thereby preventing HJ formation and 
potential exchange of sequence. In addition, it is possible that the basic domain 
of TRF2 blocks branch migration of TRF2, thereby also repressing HJ formation 
and preventing T-SCEs.  
Rap1 was not required for the maintenance of several other features of 
mouse telomeres including the amount of the single-stranded overhang, the level 
of telomeric transcripts and the telomeric chromatin state and organization. In 
budding yeast, Rap1 has been proposed to facilitate heterochromatin assembly 
by recruitment of Sir3 and Sir4 that interact with the N-termini of histones H3 and 
H4 231-233. Despite a proximity-based screen identifying potential interactions 
between Rap1 and histones H2A and H4 226, Rap1 does not seem to play a role 
in maintaining telomeric chromatin.  
Surprisingly no gross aberrations in telomere length in Rap1 null cells 
were observed either, although small differences may be difficult to discern due 
to the long telomeres of mouse cells. Studies of Rap1’s involvement in telomere 
length regulation may be more illuminating in human cells that have shorter 
telomeres.   
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How Rap1 represses HDR is not clear. It is possible that it functions by 
recruiting another protein with its BRCT domain or MYB motif, which are 
proposed to be protein-interaction domains (reviewed in 227). Factors known to 
interact with Rap1 include the Rad50 and Mre11 components of the MRN 
complex 78, which contributes to 5’ resection during HDR. However, the telomeric 
overhang is not altered in Rap1/Ku70-deficient MEFs 19, suggesting Rap1 does 
not play a major role in modulating resection at telomeres. Therefore it seems 
unlikely that Rap1 would inhibit telomeric HDR by limiting or preventing resection 
by MRN. The Rap1/TRF2 complex also interacts with the protein scaffold SLX4 
225, which binds to a HJ resolvase Mus81/Eme1. It is possible that Rap1 
modulates the activity of one of the nucleases in the SLX4 complex to interrupt 
HDR.  
In this chapter, Rap1 mutants were analyzed to determine which domains 
of Rap1 were required for repression of T-SCEs. These experiments identified 
the C-terminus of Rap1 as the important functional domain in the inhibition of 
HDR. Further investigation suggested that TRF2/Rap1 complex formation was 
necessary for HDR repression and preliminary experiments to assess the DNA-
binding activity of this complex were conducted. 
The repression of HDR also requires the presence of either of the two 
POT1 proteins 155. POT1a/b bind to single-stranded telomeric DNA and may 
inhibit initiation of HDR by preventing loading of Rad51 onto ssDNA. In the 
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context of POT1a/b- and Ku70-deficiency, Rap1, which remains at telomeres, is 
incapable of repressing HDR. The converse is true of POT1a/b that remain at 
telomeres when Rap1 is deleted, but cannot inhibit HDR 19. These data raise the 
possibility that Rap1 and POT1 may act together to repress HDR. To investigate 
whether Rap1 and POT1 are epistatic in their repression of HDR, an shRNA to 
TPP1 was used to remove POT1 from telomeres in Rap1/Ku70-deficient cells. 
No change in the level of T-SCEs would suggest that Rap1 and POT1 are 
epistatic, possibly acting together at the same step. For instance, Rap1 and 
POT1 may both interfere with Rad51 filament formation. Exacerbation of the 
occurrence of T-SCEs would suggest that Rap1 and POT1 act on distinct, non-
linear aspects of homology-directed repair, for example HJ resolution by either 
Mus81/Eme1 or GEN1.  
The lack of DNA damage signaling in Rap1/Ku70-deficient MEFs also 
provides a unique setting to study the consequences of ongoing HDR on 
telomere maintenance. As mouse cells constitutively express telomerase, this 
setting does not recapitulate ALT. However, the analysis of the long-term 
consequences of combined deficiency of Rap1 and Ku may still provide insights 
into the recombination-based mechanisms of telomere maintenance.  
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3.2 Results  
3.2.1 The C-terminus of Rap1 is required to repress telomeric HDR  
MYC-tagged alleles of mouse Rap1 containing deletions of the relevant 
motifs (BRCT, MYB, Coil) were constructed as illustrated in Figure 3.1A. 
Determination of amino acid positions of domains was based on analogous 
domain positions outlined in human Rap1 20,23. Based on the crystal structure of 
the hRap1 C-terminus in complex with a fragment of TRF2 (TRF2RBM, Rap1 
binding motif, aa 275-316) 18, the I318 residue in hRap1 was shown to be 
required for its interaction with TRF2. Co-IPs of transfected proteins from 293T 
cells showed that mutation of the analogous residue in mouse Rap1 (I312R) 
disrupted the interaction with mouse TRF2 (Figure 3.1B).  
Rap1 mutants were retrovirally expressed in Rap1F/FKu70-/- MEFs and 
immunoblotting showed that most mutants were expressed at similar levels, 
except for MYC-I312R, which was significantly overexpressed, and MYC-ΔBMC, 
which was expressed weakly (Figure 3.1C). Rap1 protein levels are diminished 
upon TRF2 depletion, yet surprisingly the Rap1 I312R mutant, which could not 
bind TRF2, was overexpressed. Therefore, it seems that when Rap1 is not bound 
to TRF2, the I312 residue is bound by another factor that targets it for 
degradation. IF-FISH indicated that all mutants, except for MYC-I312R, localized 
to telomeres (Figure 3.1D). IF for MYC-I312R showed diffuse staining throughout 
the nucleus that disappeared upon extraction of nucleoplasmic proteins with 
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TritonX-100, indicating that the Rap1 I312R mutant was not associated with 
chromatin. (Figure 3.1D). CO-FISH analysis after removal of endogenous Rap1 
with Cre revealed that all but the MYC-I312R mutant repressed T-SCEs, thus 
implicating the Rap1/TRF2 interaction in the inhibition of HDR (Figure 3.1E). 
Furthermore, the data showed that the BRCT, MYB and coiled domains of Rap1 
are not required for the repression of homology-directed repair, either individually 
or together. Although the data argue against the N-terminus recruiting an HDR-
repressing factor to telomeres, it is not excluded that the C-terminus of Rap1 
binds to TRF2 and also recruits an HDR-repressor. However, since MYC-I312R 
cannot localize to telomeres, it is possible that its deficiency in repressing HDR is 
due to lack of telomeric recruitment of a factor involved in HDR inhibition. To 
address this latter possibility, we devised a strategy to tether Rap1 to telomeres 
in the absence of TRF2.  
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Figure 3.1 The C-terminus of Rap1 is required to inhibit HDR. (A) Schematic of Rap1 domain 
mutants. * indicates I312 to R mutation. ΔBMC, deletion of N-terminal 264 amino acids (aa), 
Rap1 protein coding started at aa 265. ΔBRCT, deletion of N-terminal 106 aa, Rap1 protein 
coding started at 107 aa. ΔMYB, deletion of aa 128-196, such that aa 127 was fused to aa 197. 
ΔCoil, deletion of aa 231-264, such that aa 230 was fused to aa 265. The Rap1 antibody was 
raised to full-length protein and detects multiple antigenic regions in the N-terminus of Rap1. (B) 
293Ts were co-transfected with constructs as indicated and immunoprecipitated with a MYC 
antibody. Inputs and IPs were detected by the MYC antibody (left) and the FLAG antibody (right). 
MYC-TRF1 serves as a negative control for immunoprecipitation of FLAG-Rap1. (C) Immunoblots 
of MYC-tagged constructs in (A) expressed in Rap1F/FKu70-/-MEFs, detected with Rap1 antibody 
(left) or MYC antibody (right). All constructs except ΔBMC contain an epitope(s) for the Rap1 
antibody. n.s., non-specific band picked up by the Rap1 antibody. Running positions of constructs 
on gel are indicated on the right. (D) IF-FISH of constructs in (A) expressed in Rap1F/FKu70-/- 
MEFs. Red, IF for MYC; green, telomeric FISH, blue, DAPI DNA stain. White square shows 
corresponding area enlarged below. (E) Quantification of T-SCEs. Bars represent averages from 
three independent experiments (n~1000 chromosome ends each) and SDs. P values based on 
Student’s two-tailed t-test.  
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3.2.2 Rap1 does not inhibit HDR at telomeres lacking TRF2 
Full-length TRF2 and a 41 amino acid fragment of TRF2 (TRF2RBM) bind to 
Rap1 in vitro with similar affinities as determined by isothermal titration 
calorimetry 18. The sequence encoding these 41 amino acids was inserted into 
MYC-tagged TRF1 (TRF1RBM) with the aim of allowing TRF1 to recruit Rap1 to 
telomeres in the absence of TRF2 (Figure 3.2A). Expression of TRF1RBM in 
TRF2F/FKu70-/- MEFs showed that endogenous levels of Rap1 could be restored 
upon Cre-mediated deletion of TRF2 (Figure 3.2B). ChIP confirmed retention of 
Rap1 at telomeres despite removal of TRF2, while the telomeric occupancy of 
other shelterin components was not affected (Figure 3.2C-D). IF-FISH further 
illustrated that both endogenous Rap1 and TRF1RBM co-localized with telomeres 
(Figure 3.2E). IF for MYC displayed an unusual staining pattern of circular 
patches in the nucleus due to non-specific association of the secondary antibody, 
however magnification of insets show that MYC-tagged TRF1RBM localized to 
telomeres (Figure 3.2E). Expression of TRF1RBM in TRF1-deficient MEFs 
repressed the occurrence of fragile telomeres (Figure 3.3A-B), which are induced 
upon loss of TRF1 156,157. Thus, introduction of the RBM sequence into TRF1 did 
not disrupt normal functions of TRF1 and allowed for the retention of Rap1 at 
telomeres lacking TRF2. However, despite the presence of Rap1 at telomeres, T-
SCEs were not repressed when TRF2 was deleted from TRF2F/FKu70-/- MEFs 
(Figure 3C-D), pointing to a requirement for the interaction between Rap1 and 
TRF2 in the inhibition of HDR. Rap1 binding to TRF2 may be required for a 
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conformational change of the complex that facilitates recruitment of an additional 
protein involved in the repression of homology-directed repair. Alternatively, 
Rap1 may change the DNA binding activity of TRF2, perhaps by changing its 
affinity to DNA structures that resemble substrates for HDR, such as the telomere 
terminus.  
In addition to induction of telomere-sister chromatid exchanges, a low 
percentage of alt-NHEJ mediated telomere fusions are also observed in 
TRF2/Ku70-deficient MEFs 120. Placement of Rap1 at telomeres by TRF1RBM did 
not inhibit these fusions (Figure 3.3E) indicating that Rap1 does not play a role in 
the repression of alt-NHEJ. In contrast to these results, another study shows that 
tethering Rap1 to HeLa (a human cervical carcinoma cell line) telomeres by a 
fungal telomere-binding domain can repress c-NHEJ-mediated fusions when 
TRF2 is depleted 160. It remains to be seen whether retention of Rap1 by 
TRF1RBM can inhibit c-NHEJ mediated telomere fusions in TRF2-null MEFs.  




Figure 3.2 Tethering Rap1 to telomeres in the absence of TRF2. (A) Schematic illustrating 
composition of the TRF1RBM allele. 41 aa encoding RBM was inserted into TRF1 at position aa 
278. This did not interfere with the Bloom (BLM) helicase interaction sites shown in purple, or 
disrupt any other known interaction or nuclear localization signal. (B) Immunoblot showing 
expression of TRF1RBM in TRF2F/FKu70-/- MEFs and levels of Rap1 before and 96 hours after 
deletion of TRF2 with Cre. (C) ChIP for shelterin components and MYC-tagged TRF1RBM at 
telomeres before and 96 hours after deletion of TRF2. Dot blot was probed with TTAGGG 
repeats. (D) Relative telomeric ChIP signals obtained as in (C) were expressed as the ratio of 
signal in minus and plus Cre samples. Minus Cre set to 1. Values with error bars represent 
averages of two experiments. Error bars represent SEM. (E) Combined IF for MYC (orange) to 
detect TRF1RBM, for Rap1 (red) and FISH for telomeres (green). Blue in merged image: DAPI 





Figure 3.3 Rap1 cannot repress HDR in the absence of TRF2. (A) Immunoblot of TRF1RBM 
expressed in TRF1F/F Cre-ERT2 (tamoxifen inducible Cre expression) MEFs where endogenous 
TRF1 was deleted by treatment with 4-hydroxytamoxifen (4-OHT). (B) Quantification of fragile 
telomeres of cells in (A) before and 96h after treatment with 4-OHT. Bars represent mean values 
of three independent experiments with SDs. P values derived from two-tailed Student’s t-test. (C) 
COFISH of TRF1RBM-expressing TRF2F/F Ku70-/- MEFs before and 96 hours after treatment of 
Cre. White arrows point to T-SCEs. (D) Quantification of T-SCEs as shown in (C). Bars represent 
mean values of three independent experiments with SDs. P values derived from two-tailed 
Student’s t-test. (E) Quantification of chromosome fusions on metaphase spreads of cells in (D). 
Bars represent mean values of three independent experiments with SDs. Student’s t-test 
indicated lack of significance between Cre-treated TRF2F/F Ku70-/- MEFs expressing vector 
control or TRF1RBM.  
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3.2.3 Rap1 confers an increase in TRF2 DNA binding affinity.  
To test the hypothesis that Rap1 changes the interaction of TRF2 with 
certain DNA substrates, nickel-affinity purifications of baculovirus-expressed His-
Rap1, His-TRF2, and the His-Rap1/TRF2 complex were performed (Figure 3.4A). 
For purification of the Rap1/TRF2 complex, His-hRap1 and hTRF2 were co-
expressed in Sf9 insect cells. Immunoblotting of the co-purified Rap1/TRF2 
complex showed the expected 1:1 stoichiometry of Rap1 and TRF2 (Figure 
3.4B). Electrophoretic mobility shift assays (EMSAs) with a duplex telomeric 
substrate with 12 repeats showed the Rap1/TRF2 complex had a slight increase 
in DNA binding affinity (less than 2-fold) over TRF2 alone (Figure 3.4C). Mixing of 
separately purified Rap1 and TRF2 did not result in this improved binding affinity 
and the pattern of the shifted probe looked very similar to TRF2 alone, 
suggesting that Rap1/TRF2 complex formation was not efficient in vitro (Figure 
3.4C). Analysis of binding to a ds-ss ‘junction’ indicated that the co-purified 
complex bound to the junction substrate with a higher affinity than TRF2 alone 
(Figure 3.4D). Binding of TRF2 to the junction probe was variable with an affinity 
ranging from 2.5- to 6-fold less than that of the Rap1/TRF2 complex. Despite the 
ability of Rap1/TRF2 to bind to the junction probe better than TRF2 alone, its 
affinity for a telomeric junction was very similar to its affinity for duplex telomeric 
DNA. Therefore, while Rap1 clearly increases the DNA binding affinity of TRF2, it 
is unclear whether it is this activity of Rap1 that confers its inhibition of HDR. The 
length of the telomere tract did not affect Rap1/TRF2 binding ability, as EMSAs 
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with a duplex DNA substrate with three telomere-repeats (like the junction probe) 
did not show a change in DNA-binding affinity. Rap1 has previously been shown 
not to bind duplex telomeric DNA 20 and similarly did not exhibit any DNA binding 
to the junction probe (Figure 3.4D). Taken together these data suggest that Rap1 
binding to TRF2 improves its ability to bind telomeric DNA. However, a significant 
difference was not observed in the binding affinity of Rap1/TRF2 to a ds-ss 
telomere junction relative to duplex telomeric DNA. Therefore it remains unclear 
whether Rap1 inhibits HDR by altering the DNA binding activity of TRF2. 
3.2.4 HDR is not aggravated by dual absence of Rap1 and POT1 
To test whether Rap1 and POT1 repress HDR at the same step, I created 
and analyzed cells in which both Rap1 and POT1 were removed from telomeres. 
An shRNA to TPP1 was used to deplete POT1a/b from telomeres in 
Rap1F/FKu70-/- MEFs. As a control, TPP1 was also depleted in Rap1F/FKu70+/- 
MEFs, where the presence of one allele of Ku is sufficient to inhibit T-SCEs. The 
level of TPP1 knockdown could not be assessed by immunoblotting due to lack 
of a good antibody for mouse TPP1. However, the TPP1 shRNA was effective in 
POT1a/b removal as indicated by the induction of TIFs (Figure 3.5A-B) as well as 
the appearance of T-SCEs in Ku70-deficient cells (Figure 3.5D-E). Deletion of 
Rap1 with Cre (Figure 3.5C) in TPP1-depleted cells did not exacerbate the T-
SCE phenotype (Figure 3.5D-E). In fact the levels of T-SCEs observed in a Ku70-
deficient background when Rap1 or POT1 alone were depleted, was very similar 
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to telomeres lacking both Rap1 and POT1. Telomeres remained shielded from 
HDR when Rap1 and POT1 were removed in Ku70-proficient cells. These data 
suggest that Rap1 and POT1 act together to repress HDR.  
One caveat to consider with the interpretation of these results is whether it 
is possible to observe an exacerbation of the T-SCE phenotype. Theoretically, 
assuming HDR intermediates can be equally shuttled into pathways that dissolve 
the Holliday junction or resolve it resulting in crossover, the maximal number of 
T-SCEs we would expect to detect is 50%. Current levels of T-SCEs observed 
are rarely above 15%. Various efforts to knockdown BLM or TOP3α to remove 
the dissolution arm of HDR and skew resolution of HDR intermediates into 
crossovers were unsuccessful, therefore it remains to be seen what the threshold 
of detection for T-SCEs is.  
Despite this caveat, these results raise the possibility that Rap1 and POT1 
repress HDR as a subcomplex of shelterin. Indeed it has been shown that TRF2 
and POT1 are capable of forming a detectable complex 21,152,185,234. However, 
coimmunoprecipitation experiments failed to detect a stable interaction between 




Figure 3.4 Rap1 confers an increase in the telomere binding affinity of TRF2.  
(A) Coomassie stained SDS-PAGE gels of purified His-tagged proteins as indicated. 2-fold serial 
dilutions of purified protein and Bovine serum albumin (BSA) were run on the same gel to quantify 
protein amounts. (B) Immunoblotting of quantified protein amounts to calculate stoichiometry of 
Rap1 and TRF2 in the co-purified sample. (C) Top, schematic of probe (restriction fragment 
containing 12 TTAGGG repeats) used for EMSAs below. Bottom, EMSAs with 2-fold serial 
dilutions of indicated proteins; probe, no protein added. Dissociation constants (Κd) calculated 
below. Values for co-purified and TRF2 are mean of three experiments with SDs. (D) Top, 
schematic of probe with 3 TTAGGG repeats, a 3’ overhang containing the minimal binding site for 
POT1 (5’-GGTTAGGGTTAG-3’), and a natural telomere end (ATC-5’). Bottom, EMSAs with probe 
above using 2-fold serial dilutions of indicated proteins; probe, no protein added. Dissociation 
constant (Κd) calculated below. Value for co-purified is mean of three experiments with SDs; n.d., 
not determined.   
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Figure 3.5 No exacerbation of T-SCE levels upon removal of Rap1 and POT1. (A) TIF assay 
on Rap1F/FKu70-/- or Rap1F/FKu70+/- MEFs treated with Cre and or a TPP1 shRNA as indicated for 
96 hours. White square indicates area enlarged below. (B) Quantification of TIF-positive cells as 
in (A). Cells with ≥ 10 TIFs were considered TIF-positive. Bars represent mean values of three 
independent experiments with SDs. (C) Immunoblot for Rap1 in cells as described in (A). (D) CO-
FISH assay on cells as described in (A). White arrows indicate T-SCEs. (E) Quantification of CO-
FISH in (D). Bars represent mean values of three independent experiments with SDs. P-values 
calculated based on Student’s t-test. (F) MYC-immunoprecipitation from 293T cells co-transfected 
with MYC-tagged constructs as indicated and FLAG-tagged Rap1. MYC-TRF2ΔRap1 was used as 
a negative control and MYC-TRF2 was used as a positive control for interaction with Rap1.  
 70 
3.2.5 Deletion of Rap1 and TRF1 does not induce T-SCEs 
TRF1 loss results in inefficient replication of telomeric DNA 156 and 
potentially introduces replication intermediates that are susceptible to resolution 
by homology-directed repair. However, T-SCEs are not observed when telomeres 
lack TRF1, possibly due to repression of HDR by Ku70/80. Indeed, preliminary 
analysis of MEFs lacking TRF1 and Ku80 showed an induction of T-SCEs 
(Figure 3.6A), suggesting that telomeres are also vulnerable to HDR during DNA 
synthesis.  
Mass spectrometry and ChIP experiments using human cells have 
implicated shelterin components TRF1, TRF2 and Rap1 in interacting with and 
potentially recruiting Ku to telomeres 78, 265, 283, although Ku has also been shown 
to bind directly to telomere repeats in vitro 284. To explore potential redundancy in 
the recruitment of Ku to telomeres, we decided to delete both Rap1 and TRF1 
from telomeres. If T-SCEs were observed in Rap1/TRF1 null MEFs, this would 
suggest that Ku is unable to repress HDR in this setting. Alternatively, removing 
both Rap1 and TRF1 could lead to an increase in telomere substrates vulnerable 
to HDR and result in T-SCEs regardless of whether co-repression of HDR by Ku 
was functional or not. 
Analysis of metaphases lacking Rap1 and TRF1 in a Ku-proficient setting 
showed an increase of fragile telomeres and telomere sister associations which 
are characteristic of TRF1 loss (Figure 3.6B-C). Despite the presence of telomere 
replication problems, no induction of T-SCEs was observed (Figure 3.6C), 
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suggesting that Ku was still able to repress HDR. A low level of telomere fusions 
were also detected in MEFs where Rap1 and TRF1 had been deleted (Figure 




Figure 3.6 Ku represses T-SCEs in TRF1 null cells, as well as in MEFs lacking both Rap1 
and TRF1. (A) Quantification of T-SCEs (left) and telomere sister associations (right) on 
metaphase spreads, before and 96 hours after treatment with Cre. Genotypes as indicated. (B) 
Western blot of two littermate controls with genotypes as indicated, before and 96 hours after 
treatment with Cre. Antibodies used for detection of proteins are indicated on left. (C) 
Quantification of aberrant structures on metaphase spreads in Rap1F/F TRF1F/F MEFs before 
and 96 hours after treatment with Cre. Data represents averages and standard deviations from 
analysis of three independently derived cell lines.   
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3.2.6 HDR is repressed in late-passage Ku70-deficient MEFs 
The induction of homology-directed repair in absence of DNA damage 
signaling and cell cycle arrest in Rap1/Ku70-deficient MEFs allowed examination 
of the consequences of unbridled HDR on telomere maintenance. Rap1F/F Ku70-/- 
(or Rap1F/Δ Ku70-/-) MEFs were isolated and immortalized with SV40LT. The 
immortalization process is variable and takes approximately 15 to 20 PDs for 
cells to escape crisis and proliferate at a steady pace. The number of PDs cells 
undergo during immortalization is a reproducible estimate, but cannot be exactly 
calculated due to cell death or senescence that primary MEFs undergo during the 
immortalization process. After immortalization, at approximately PD 20, 
Rap1F/FKu70-/- (or Rap1F/ΔKu70-/-) MEFs were further cultured to 70 PDs with and 
without Cre treatment (Figure 3.7A-B). Cells were harvested at various time-
points to assess the level of T-SCEs. Surprisingly, T-SCE events began to 
diminish as early as PD 30 and were reduced to basal levels similar to Rap1-
proficient cells by PD 50 (Figure 3.7C). T-SCEs were also no longer induced 
when Rap1 was deleted from late passage Rap1F/F Ku70-/- showing that Ku70-
deficient MEFs exhibit downregulation of telomeric HDR when cultured 
extensively.  
To determine whether HDR was downregulated in general or just at the 
telomere, efforts were made to use a transient reporter assay developed in the 
Jasin lab 171 that assesses HDR-mediated repair events of a break induced by 
expression of I-SceI (a site-specific endonuclease). However this assay did not 
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work robustly in MEFs, due to difficulty in achieving high transfection efficiencies 





Figure 3.7 HDR is repressed in late-passage Ku70-deficient MEFs. (A) Growth curve of 
Rap1F/FKu70-/- MEFs with and without deletion of Rap1 by Cre. (B) Western blot indicating Rap1 
levels in the two cell lines shown in (A) at the indicated PDs. (C) CO-FISH analysis of Ku70 
deficient MEFs with or without Rap1 at the indicated PDs. White arrows point to T-SCE events. 
Quantification of chromosome ends with T-SCEs for three independent experiments is listed 
under corresponding CO-FISH panels. 
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3.3 Summary of findings 
The data presented here show that Rap1 requires its interaction with 
TRF2 to repress HDR. Recruitment of Rap1 to telomeres by TRF1RBM in the 
absence of TRF2 did not prevent T-SCEs. It is possible however, that 
experimentally induced binding of Rap1 to TRF1RBM may disrupt Rap1’s 
interaction with another factor required for repression of HDR. Additionally, the 
specific localization of Rap1 at telomeres by TRF1RBM may be subtly, yet 
impactfully different compared to its placement byTRF2.  
The Rap1/TRF2 complex may bind to a protein involved in HDR inhibition 
that Rap1 alone or TRF2 alone may be unable to bind to. Alternatively, Rap1 
may enhance the DNA binding affinity of TRF2 to HDR substrates and prevent 
loading of components required for repair. Preliminary gel-shift assays indicated 
that Rap1 may enhance the overall binding affinity of TRF2 to telomeric DNA, but 
this effect was minor and it is unclear whether it would be physiologically 
relevant. However, one report showed that the Rap1/TRF2 complex binds to ds-
ss telomere junctions 10-fold better than duplex DNA 235. The discrepancy 
between this study and the results reported here could be due to changes in the 
activity or oligomeric state of the purified proteins, as well as the different 
substrates used. In addition, another study reported Rap1 conferred no 
advantage to TRF2 to bind ds-ss telomere junctions, but instead improved the 
specificity of TRF2 binding to telomeric DNA 236.  
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Rap1 and POT1a/b seem to inhibit HDR via the same pathway as no 
increase in the number of T-SCEs was observed when Rap1 and POT1a/b were 
all removed from telomeres in a Ku70-deficient setting. Further assessment of 
Rap1/TRF2 DNA-binding needs to be conducted in the context of the shelterin 
complex, as POT1 binding to the overhang together with Rap1/TRF2 binding to 
the ds-ss junction may contribute to the repression of telomeric HDR. 
Lastly, the surprising finding that Ku70-deficient cells eventually 
downregulate HDR suggests that when Ku is unable to inhibit HDR other factors 
may be enlisted to regulate HDR. Efforts to determine whether this repression of 
HDR was global or telomere-specific have thus far been unsuccessful and 
warrant further study.  
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Chapter 4: TALEN gene knockouts of human Rap1  
 77 
4.1 Introduction 
Two discrepancies exist concerning the function of Rap1 in mammals. In 
vitro, human Rap1 can block NHEJ when it binds to TRF2 loaded on an end-
joining substrate 213. In vivo, a Rap1-fusion protein can reduce telomere fusions 
when it is tethered to telomeres that are depleted of TRF2 160. On the other hand, 
mouse cells lacking Rap1 show no telomere fusions and Rap1-deficient mice are 
alive and fertile 19,220. The only telomere deprotection phenotype in Rap1-
deficient mouse cells is a propensity for telomere-telomere recombination when 
Ku70/80 are also absent 19. 
In addition, it is unclear whether Rap1 has a conserved role in telomere 
length homeostasis in mammals. In support of a role in telomere length control, 
shRNAs to human Rap1 induce telomere lengthening 78, as does overexpression 
of several Rap1 truncation mutants 23. Furthermore, overexpression of Rap1 
mutants lacking its BRCT domain or MYB motif exhibit diminished telomere 
length heterogeneity, suggesting Rap1 also has a role in regulating distribution of 
telomere length. However, Rap1 knockout mice show no change in telomere 
length, even after three generations 19.  
To determine the function(s) of human Rap1, Transcription Activator Like 
Effector Nucleases (TALENs) were used to knockout the Rap1 gene. Analysis of 
several independent Rap1-deficient cell lines demonstrated that human Rap1 
was not required for telomere protection, telomere length regulation, and other 
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aspects of telomere function. Instead, changes were observed in the transcription 
of several genes upon loss of Rap1. 
4.2 Results  
4.2.1 Efficient TALEN-mediated knockout of human Rap1  
Similar to the mouse, the human Rap1-encoding gene (TERF2IP, referred 
to as Rap1) shares its promoter region with the essential KARS (lysyl-tRNA 
synthetase) gene located just upstream of exon 1 (Figure 4.1A). To avoid 
disrupting the KARS gene, a targeting strategy analogous to the one used for 
mouse Rap1 19 was implemented and TALENs were employed to delete exon 2. 
Deletion of exon 2 should result in an mRNA encoding a 226 aa ORF that ends 
prematurely in a stop codon at the beginning of exon 3. As exon 3 encodes the 
TRF2-binding domain, the truncated Rap1 protein is not expected to localize to 
telomeres. Taking advantage of the small size of exon 2 (125 bp) and anticipated 
resection of TALEN-induced DSBs 237,238, a neomycin or blasticidin donor 
construct was designed containing 5’ and 3’ arms homologous to the surrounding 
introns. HDR using the donor construct should result in deletion of exon 2 and 
insertion of the neomycin cassette (Figure 4.1A).  
Rap1 was targeted in two near-diploid cancer lines (HCT116 colorectal 
carcinoma and HT1080 fibrosarcoma), a subclone of the near-triploid cervical 
carcinoma HeLa cell line (HeLa1.3 22), the diploid ARPE-19 retinal pigment 
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epithelial cell line, and primary BJ fibroblasts transformed with SV40LT. With the 
exception of BJ-SV40LT, all cells expressed telomerase. For HCT116, HT1080, 
and ARPE-19 cells, neomycin resistant clones were obtained, analyzed by PCR, 
and then evaluated by Southern blotting to verify the correct neomycin insertion 
(Figure 4.1B-C). For HeLa1.3 and BJ-SV40LT, the blasticidin donor construct 
was used and clones were analyzed by immunoblotting for Rap1. These 
analyses identified clones that lacked the wild type Rap1 gene and expressed no 
detectable Rap1 protein (Figure 4.1C-D). Polypeptides representing the 
remaining ORF of the targeted Rap1 gene were not detected (Figure 4.2A-C), 
perhaps due to nonsense-mediated decay.  
Unexpectedly, immunoblotting revealed the complete loss of Rap1 in 
heterozygous clones with one neo insertion (Figure 4.1B-C). Telomeric ChIP of 
two such clones (HT1080 c21 and HeLa1.3 c28) confirmed that Rap1 was absent 
from telomeres (Figure 4.2D-G). Sequencing revealed small deletions close to 
the TALEN site in these and other Rap1-deficient clones with only one neo-
containing Rap1 gene (Figure 4.3A-B). Most mutations had ablated Rap1 by 
deleting the exon 2 splice acceptor site or had created a frame-shift mutation, 
indicating that errors generated during NHEJ had inactivated the Rap1 gene 
(Figure 4.3C). As a result, the frequency of the Rap1 knockouts (KOs) is much 
higher than deduced from PCR genotyping. Taking the deleterious repair events 
into account, the ablation of Rap1 occurred at 20-65% efficiency in HCT116, 
HT1080, and ARPE-19 cells (Figure 4.3D). The HCT116 cells showed the 
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highest KO frequency consistent with their propensity for HDR (reviewed in 239). 
The actual KO frequency is probably even higher as only clones with a neo 
cassette in the Rap1 gene were analyzed.  
The high KO frequency allowed screening of HeLa1.3 and BJ-SV40LT 
clones by Rap1 immunoblotting. Sequencing of Rap1-negative HeLa1.3 clones 
revealed that all three alleles in these clones contained inactivating mutations 
near the TALEN cut site (Figure 4.3B). Prolonged culturing of clones in blasticidin 
resulted in cell death, suggesting that the pEF blasticidin cassette did not confer 
long-term resistance. The KO frequency was lower in BJ-SV40LT fibroblasts with 
only one blasticidin-resistant clone showing absence of Rap1 protein. This clone 
was not analyzed because it perished in telomere crisis, as did many of the 






Figure 4.1 TALEN-mediated inactivation of the gene for human Rap1. (A) Schematic of 
human Rap1, the Rap1 locus, the targeting construct, and the resulting knockout allele. F1, R1, 
and R2neo: PCR primers for genotyping. Arrows in bold: TALEN binding and cut sites. (B) 
Southern blot of EcoRI (RI)- or BglII/EcoRV (RV)-digested genomic DNA from targeted HT1080 
clones. Probe shown in (A). (C) PCR genotyping of the Rap1 gene and western blotting for Rap1 
in the indicated clones. +, WT allele; Δ, targeted allele; mut, mutation resulting in loss of Rap1. 
(D) Immunoblotting of protein from targeted homozygous and heterozygous HCT116 clones 







Figure 4.2 Loss of Rap1 in targeted clones. (A) Immunoblots of HCT116 and HT1080 KO 
clones probed with anti-hRap1 showing the absence of detectable truncated Rap1 proteins. (B) 
Schematic of retroviral constructs expressing FLAG-tagged exon 1 (ex 1) and FLAG-tagged exon 
3 (ex 3). (C) Immunoblotting for the expression of constructs in (B) in HT1080 KO and WT clones. 
The protein fragment encoded by exon 1 is expressed and detected by the Rap1 antibody. The 
protein fragment encoded by exon 3 contains epitopes that the Rap1 antibody can recognize, but 
lack of detectable signal indicates that it is not expressed. (D) Telomeric ChIP of WT and targeted 
HT1080 clones. Duplicate dot-blots were probed for telomeric or Alu repeats. (E) Average 
percentage of telomeric DNA recovered in ChIPs with the indicated antibodies (two independent 
experiments). Error bars: SEMs. (F) Telomeric ChIP of HeLa 1.3 WT and KO cells. (G) 
Quantification of the percent of telomeric DNA recovered in each ChIP.  
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Figure 4.3 TALEN-induced mutations in the Rap1 locus. (A) Schematic illustrating TALEN 
binding sites, their predicted cutting site (grey arrows), the pyrimidine tract, splice acceptor (SA), 
and the location of exon 2 in the Rap1 locus. A short repeat (underlined in grey) is frequently 
mutated in the mutant alleles. (B) Relevant sequences of the indicated clones. Predicted 
consequences of the mutations are indicated on the right. (C) Schematic illustrating NHEJ and 
HDR after TALENs cutting. (D) Table indicating number of Rap1 knockout clones acquired and 
the genetic alterations in Rap1.  
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4.2.2 Rap1-deficient cell proliferate and maintain fully protected telomeres 
The Rap1-deficient cell lines proliferated normally (Figure 4.4A) and 
lacked a significant level of TIFs (Figure 4.4B-C), indicating that removal of Rap1 
from telomeres does not result in a DNA damage response. Cells lacking Rap1 
also did not show a significant induction of DSB repair at telomeres. Metaphase 
spreads of Rap1 KOs lacked chromosome end fusions, a read-out for telomeric 
NHEJ (Figure 4.5A-B). CO-FISH to monitor HDR-mediated T-SCEs established 
that recombination remained repressed at telomeres (Figure 4.5C-D). Analysis of 
telomere-sister chromatid exchanges in cells lacking Rap1 was conducted in a 
Ku-proficient background. Similar to the mouse, human Ku70/80 are also 
required to repress telomere recombination. However, unlike the mouse, deletion 
of Ku70/Ku80 is lethal in human somatic cells 240,241, thus it was not possible to 
test a setting where both Rap1 and Ku70/80 were deleted. While the contribution 
of human Rap1 to the repression of HDR in the context of Ku70/80-deficiency 
remains to be determined, our data indicate that human telomeres remain 
protected from NHEJ and HDR in absence of Rap1. 







Figure 4.4 Rap1-deficient cells proliferate and do not induce DNA damage signaling.  
(A) Growth curves of WT and Rap1 KO HT1080 clones. (B) TIF assay on WT and KO HeLa1.3 
clones. Green, telomeric FISH; red, IF for 53BP1; blue, DNA (DAPI). (C) Quantification of TIFs 
assay (see (B)). Error bars: SDs of three independent experiments (n≥100 nuclei per clone). P 
values from a two-tailed paired t-test combining WT and KO datasets. n.s.: not significant.  
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Figure 4.5 Telomere protection in Rap1-deficient cells. (A) Metaphase chromosomes from 
the indicated WT and Rap1 KO cells. Green, telomeric FISH; blue, DNA (DAPI). (B) 
Quantification of telomere fusions, detected as in (A), in the indicated clones. P values from a 
two-tailed paired t-test on combined WT and KO datasets. (C) CO-FISH analysis on the indicated 
WT and KO HeLa clones. (D) Table showing the percentage of telomeres showing T-SCEs as 
assayed in (C) in the indicated clones. P value from unpaired two-tailed t-test.   
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4.2.3 Unaltered telomere length dynamics in absence of Rap1.  
To determine whether Rap1 affected telomere length homeostasis, two 
HT1080 Rap1-deficient clones were cultured for 50 PDs alongside two Rap1-
proficient clones selected for their matching telomere lengths (Figure 4.6A). All 
clones exhibited a mild increase in telomere length (Figure 4.6B). The two Rap1-
deficient clones lengthened their telomeres at a similar modest rate (1-2 bp/PD) 
whereas the two Rap1-proficient clones differed in the rate of telomere 
lengthening (28 and 4 bp/PD) (Figure 4.6B). Given the clonal variation and small 
differences in telomere length changes, the removal of Rap1 did not appear to 
have a strong effect on telomere length dynamics in HT1080 cells.  
Similarly, Rap1 did not affect the telomere length dynamics of HCT116 
clones (Figure 4.6C). Two Rap1-deficient clones showed telomere shortening at 
variable rates (-3 to -32 bp/PD). Given that the telomere shortening in the 
parental cells (-27 bp/PD) is similar to that of one of the Rap1-deficient clones 
(c10), it can be concluded that Rap1 did not strongly affect telomere dynamics in 
HCT116 cells either.  
Finally, three Rap1-deficient ARPE-19 clones (c26, c25, and c30) showed 
wide variations in telomere dynamics, ranging from slight shortening (-18 bp/PD) 
to slight elongation (9 and 16 bp/PD) (Figure 4.6D). The single Rap1-proficient 
clone (c23) showed telomere shortening at a rate of -34 bp/PD. Thus, there is 
considerable variability in the telomere dynamics in ARPE-19 clones but no 
consistent effect of Rap1 deletion.  
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Given the lack of consistent shortening or lengthening phenotypes in 
multiple Rap1 knockouts, the simplest interpretation is that Rap1 does not play a 
major role in telomere length regulation. Deletion of Rap1 also did not induce an 
obvious change in the telomere length heterogeneity (Figure 4.6A and 4.7A), 
which was affected by Rap1 mutants in overexpression studies 20. Removal of 
Rap1 from several cell lines also did not appear to affect the 3’ telomeric 
overhang. The amount of ss telomeric DNA was determined by in-gel 
hybridization of a labeled C-strand telomeric repeat probe to native telomeric 
restriction fragments. Quantification of normalized single-stranded telomeric DNA 
signals indicated that Rap1 status had no significant impact on the 3’ overhangs 
in HT1080, HCT116, and ARPE-19 cells (Figure 4.7A-B). 





Figure 4.6 Rap1 knockouts exhibit no systematic changes in telomere length. (A) Southern 
blot of telomeric restriction fragments from two WT and two KO HT1080 clones at the indicated 
PDs.(B-D) Curves of average telomere lengths at indicated PDs in HT1080, HCT116, and ARPE-
19 clones, respectively.  
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Figure 4.7 Loss of Rap1 does not affect telomere structure. (A) Telomeric DNA analysis of 
WT and KO clones in three different cell lines. Top, in-gel detection of native telomeric restriction 
fragments with a C-strand telomeric probe revealing the G-strand overhang signals; bottom, 
same gel rehybridized after in situ denaturation of the DNA, revealing the total telomeric DNA in 
each lane. Three biological replicates of each cell line were run adjacent to each other on the 
same gel. (B) Overhang signals were normalized to total telomeric signals in each lane and 
plotted as a ratio compared to the WT overhang signal of the corresponding cell line. Error bars 
represent SDs. Lack of statistical significance derived from two-tailed paired t-tests using the 
three independent experiments conducted with each cell line.  
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4.2.4 Telomeric positioning in Rap1 null cells 
To determine whether Rap1 is involved in the peripheral positioning of 
telomeres in newly formed G1 cells 219, mitotic shake-off was used to analyze 
HeLa1.3 daughter cells in early G1. HeLa cells were used due to the ease of 
detection of their long telomeres, and the same method of telomere position 
analysis had been previously conducted in HeLa cells 219, thereby enabling a fair 
comparison to published data.  
Using Lamin A to mark the nuclear envelope (NE) and FISH to visualize 
telomeres, the subnuclear position of the telomeric signals was determined and 
compared between Rap1-proficient and -deficient cells (Figure 4.8A-B). The 
distribution of telomeres in the nucleus and median distance from the nuclear 
envelope was similar for two Rap1-proficient and -deficient clones in two 
independent experiments. Moreover, the percentage of telomeres present in a 
zone defined arbitrarily as the nuclear periphery (within 10% distance from the 
NE) was also similar regardless of Rap1 status, illustrating that Rap1 is not 




Figure 4.8 Effects of Rap1 on telomere position. (A) Combined IF for lamin A (red) and FISH 
for telomeres (green) in early G1 nuclei of WT and Rap1 KO HeLa1.3 clones. The scale in one 
nucleus indicates how the position of the telomeric signals was determined. Blue: DAPI DNA 
stain. (B) Distance of telomeres from nuclear envelope (NE) in arbitrary units. For each nucleus 
imaged in a single plane, the ratio between the distance of each telomere from the center and the 
radius (center to NE) was plotted. Median distance for each clone is indicated by horizontal line. 
% telomeres at periphery reflects telomeres within 10% of the distance from the NE. Two 
independent experiments for each clone are shown.  
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4.2.5 No change in telomeric chromatin or transcription upon Rap1 loss 
Mammalian telomeres contain nucleosomes and epigenetic marks that are 
characteristic of heterochromatin, such as H3K9me3, H4K20me3 and the loading 
of heterochromatin protein 1 (HP1, reviewed in 228). Rap1 also had no detectable 
effect on general markers for the chromatin status at telomeres, as evidenced by 
ChIP for methylation of H3K9, acetylation of H4, and HP1α, HP1β and HP1γ 
(Figure 4.9A-B). In addition there was no significant effect of Rap1 on the 
abundance of the telomeric lncRNA TERRA (Figure 4.9C-D). This finding is 
consistent with the unaltered TERRA levels after deletion of mouse Rap1 19. 
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Figure 4.9 No change in telomeric chromatin or transcription in Rap1-deficient cells.  
(A) ChIP for modified histones at telomeres in WT and Rap1 KO cells. Duplicate blots were 
probed for telomeric DNA or Alu repeats. (B) Relative telomeric ChIP signals obtained as in (A) 
were expressed as the ratio of signal in KO and WT clones (WT set to 1). Values represent 
averages of two experiments. Error bars: SEMs. (C) Northern blot hybridized with a telomeric 
probe showing TERRA levels of Rap1 WT and KO clones in the HT1080, HCT116 and ARPE-19 
cell lines. U2OS serves as a positive control for TERRA expression. Ethidium bromide staining of 
ribosomal RNA serves as a loading control. (D) TERRA signals were normalized using the 18S 
ribosomal RNA and plotted as a ratio compared to the WT TERRA signal of the corresponding 
cell line. Error bars represent SDs. Two-tailed unpaired t-tests of 3 independent experiments 
illustrates lack of statistical significance between Rap1 WT and KO TERRA expression levels. 
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4.2.6 Rap1 affects transcriptional regulation 
Mouse Rap1 localizes to over 8600 gene-associated loci, affecting 
transcription of numerous genes 220-222, while human Rap1 is found at  ~63 gene 
loci 223. To query the effect of Rap1 on the transcriptome, microarray profiling 
was performed on seven Rap1 WT and KO clones derived from three different 
cell lines, ARPE-19, HT1080 and HCT116. A number of differentially regulated 
genes were identified (Tables 4.1-4.3). The three Rap1-regulated genes in the 
ARPE-19 cells (LHX2, LRRC17 and CDO1) were validated by quantitative RT-
PCR (qRT-PCR) and their response to Rap1 deletion was further confirmed on 
an additional ARPE-19 Rap1 KO clone (c26) (Figure 4.10A-C). The Rap1-
regulated genes varied between the different cell lines, most likely due to the 
different origins of the cell lines. Gene ontology analysis was uninformative, 
because of the low number of genes identified by this limited analysis. However, 
one Rap1-regulated gene in the HT1080 cells was among the human Rap1-
associated loci in the HT1080-derived HTC75 cell line 223. Taken together, these 
data are consistent with a role for Rap1 in transcriptional control in human cells.  
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Table 4.1 Microarray expression analysis for ARPE-19. 
Cell Line Gene (chromosome) [LogFC]a 
KO v WT LHX2 (chr9) LRRC17 (chr7) CDO1 (chr5) 
c25 v c23 -3.3 -5.1, -3.4 -3.5 
c30 v c23 -2.7 -5.1, -3.4 -3.8 
c25 v par -4.2 -4.6, -3.1 -3.3 
c30 v par -3.7 -4.5, -3.0 -3.5 
a,Multiple LogFC values reflect data from multiple probes for the corresponding gene. 
Table 4.2 Microarray expression analysis for HT1080. 
Cell Line Gene (chromosome) [LogFC]a 
















c8 v c2 3.0 3.4, 1.8, 2.5,  - 2.0 -3.4 -2.1 3.0 2.0, 1.7 -2.9 
c21 v c2 3.1 3.7, 1.9, 2.4, 3.0 2.2 -3.6 -2.3 2.2 2.1, 1.9 -2.3 
c8 v c9 3.8 3.6, 1.8, 2.3,  - 1.6 -2.0 -2.7 2.9 2.0, 1.7 -2.9 
c21 v c9 3.9 3.9, 1.8, 2.3, 2.8 3.5 -2.2 -2.9 2.2 2.1, 1.9 -2.3 
a,Multiple LogFC values reflect data from multiple probes for the corresponding gene. b CDCP1 
was identified as a Rap1 associated locus by ChIP-seq in a subclone of HT1080	  223 . 
Table 4.3 Microarray expression analysis for HCT116. 
Cell Line Gene (chromosome) [LogFC] a 
KO v WT BMP4 (chr14) SLC2A3 (chr12) SUSD2 (chr22) 
c10 v c15 -2.0 -3.4 -2.6 
c21 v c15 -2.1 -2.7 -2.2 
c28 v c15 -1.9 -2.3 -2.1 
c10 v c20 -2.0 -2.7 -2.0 
c21 v c20 -2.0, -2.5 -2.0 -1.6 
c28 v c20 -1.8 -1.5 -1.5 
c10 v c23 -1.8 -2.9 -2.8 
c21 v c23 -1.9, -2.4 -2.1 -2.5 
c28 v c23 -1.7 -1.7 -2.3 
a,Multiple LogFC values reflect data from multiple probes for the corresponding gene. 
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Figure 4.10 Validation of Rap1 as a transcriptional regulator. (A-C) Quantitative RT-PCR 
illustrates differential expression of three genes ((A) LHX2, (B) LRRC17, (C) CDO1) in Rap1 WT 
and KO ARPE-19 cells. Gene expression was normalized to GAPDH and mean expression level 
for each gene as determined by the ΔCt method from 3 independent replicates is graphed in 
arbitrary units. Error bars represent SDs. Significance was calculated by two-tailed unpaired T-
Tests. *** indicates p ≤ 0.001. 
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4.3 Summary of findings 
Based on the genetic data presented here, human Rap1 is not required for 
the protection of telomeres from NHEJ and has no obvious effect on telomere 
length regulation, contrary to what was anticipated from other studies 23,78,160,213. 
The results in this chapter point to the difficulty in interpreting experiments in 
which telomeric phenotypes are observed upon overexpression of shelterin 
(mutant) proteins or their partial inactivation by shRNAs. The prior finding of 
changes in telomere length and heterogeneity upon overexpression of Rap1 
mutants 23 may have been due to nucleoplasmic titration of factors away from the 
telomere that (indirectly) influence these phenotypes. Similarly, the artificial 
tethering of Rap1 to telomeres may have had an effect on NHEJ that does not 
reflect the normal function of the protein 160. 
In addition, telomeres lacking Rap1 remained protected from DNA 
damage signaling and HDR, and had a normal 3’ overhang. These findings are in 
agreement with the mouse Rap1 KO, which revealed no obvious phenotype other 
than that of telomeres becoming prone to undergo HDR when Ku70/80 was 
absent 19. Whether human telomeres lacking Rap1 also recombine more readily 
in a Ku70/80-deficient setting is difficult to assess since deletion of human 
Ku70/80 leads to rapid telomere loss and cell death 240,241. 
Human Rap1 was surprisingly dispensable for telomere protection, 
however its role in transcriptional regulation appears to be conserved. Due to the 
low number of deregulated genes identified in vastly differing cell types, it was 
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difficult to assess what transcriptional programs Rap1 participates in. 
Examination of Rap1 deletion in cell lines with high metabolic activity, such as 
hepatocytes, would help identify whether human Rap1 affects metabolism similar 
to mouse Rap1.  
These data indicate that while mammalian Rap1 has functionally diverged 
away from its yeast predecessors, mouse and human Rap1 are very similar. Both 
Rap1 knockout mice and human cells are viable, lack hallmarks of telomere 
dysfunction, and have no overt change in telomere length settings. While the 
Rap1 components of human and mouse shelterin are indistinguishable, it will be 
important to query the functions of other shelterin components and associated 
factors to gain a complete understanding of telomere maintenance and protection 
in human cells.   
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Chapter 5: Investigating the role of human POT1 at telomeres  
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5.1 Introduction 
As discussed in the general introduction, the deletion of mouse POT1a 
and –b leads to embryonic and cellular lethality, elicits a telomeric ATR 
dependent DNA damage response, increases 3’ telomere overhangs, and results 
in infrequent post-replicative telomere fusions and telomere sister associations 
31,32,182.  
In human cells, two isoforms of POT1 are detected by immunoblotting with 
molecular weights of 71 kDa and 55 kDa 184. The protein that migrates at 71 kDa 
corresponds to full-length POT1 (POT1-FL). The isoform with the molecular 
weight of 55 kDa (POT1-55) lacks the first N-terminal OB fold of POT1 and is 
unable to bind telomeric DNA 34. POT1-55 is almost identical to a mutant allele of 
POT1 (POT1ΔOB). POT1ΔOB cannot bind to telomeric DNA but retains its 
interaction with TPP1. When overexpressed, POT1ΔOB acts as a dominant-
negative 79, presumably by binding to TPP1 and displacing endogenous POT1. 
Endogenous expression levels of POT1-FL are approximately 10-fold more 
abundant than POT1-55 184, and no function has been ascribed to POT1-55 as of 
yet.  
Partial depletion of POT1-FL with shRNAs impairs the growth of primary 
but not transformed cells 184. Furthermore, there is a modest reduction (~30%) in 
the overhang signals and the precise nature of the 5’ end of the telomeres is 
disrupted 184,185. Knockdown of both POT1-FL and POT1-55 results in low levels 
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of TIFs, where ~40% of cells are TIF-positive, occurring during the G1 phase of 
the cell cycle 184.  
In addition to protecting telomeres from the DNA damage response and 
modulating the nature of the telomere terminus, POT1 has been implicated in the 
cis-acting negative regulation of telomerase. Depletion of POT1 with shRNAs 29 
or expression of the POT1ΔOB allele leads to telomere elongation 79. The POT1 
binding partner TPP1, on the other hand, interacts with telomerase and promotes 
the recruitment of the enzyme to telomeres in vivo and enhances the processivity 
of the enzyme in vitro 81.  
Although the functions of POT1a and POT1b have been examined in 
detail, it is as yet unclear to what extent the single human POT1-FL protein 
incorporates these functions, and what role POT1-55 plays, if any. To understand 
the role of human POT1 in telomere protection, we used TALENs with the aim to 
generate human knockout cell lines lacking POT1. The preliminary analysis of 
these human POT1-deficient cells is reported here. 
5.2 Results  
5.2.1 The human POT1 targeting strategy  
Mouse POT1a and –b share greater than 70% amino acid identity with 
human POT1 31. Human POT1, POT1a, and POT1b, have transcripts comprised 
of 19, 18 and 17 exons respectively, 15 of which are coding exons (annotated by 
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Ensembl). Here, coding exons are numbered sequentially with exon 1 containing 
the ATG. A strategy analogous to the mouse knockouts was employed to create 
knockouts of human POT1. The mouse knockouts of POT1a and –b were 
generated by deletion of exon 3, which results in an ORF with a premature stop 
codon in exon 4 31. In that study, exons 1 and 2 were not targeted because this 
could bring a putative alternate start site in the 5’ UTR into frame with exon 3 
coding sequences. Similar to the mouse genes, deletion of human exon 3, which 
encodes aa 41 to 85, is predicted to lead to a premature stop codon in the POT1 
ORF at a position four codons into exon 4. Thus, we decided to delete exon 3 in 
human cells to generate a POT1-FL knockout. Neomycin, blasticidin and zeocin 
donor constructs were designed with 5’ and 3’ arms homologous to the introns 
surrounding exon 3 (Figure 5.1B). The anticipated resection at the TALEN-
induced DSB and the small size of exon 3 should allow processing to extend into 
the surrounding introns such that the 5’ and 3’ arms can be used for homology-
dependent repair, such that the repaired allele lacks exon 3.  
In silico analysis of potential exon skipping products indicated that the 
ORF could be put back into frame if splicing were to occur from the exon 2 splice 
donor site to exon 7, 8, 10, 12, or 14. The potential truncated products generated 
by the exon skipping events would lack most of the N-terminal OB-folds that 
confer the ssDNA binding activity to POT1. Therefore, some of these versions of 
POT1 (splicing of exon 2 splice donor site to exon 7, 8, or 10) might still be 
recruited to telomeres via their C-terminal TPP1 binding region (encoded by 
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exons 10-15; see Figure 5.1A) and could potentially act as dominant-negative 
mutants due to loss of their OB folds 79. To circumvent the formation of these 
truncated proteins, the donor construct was endowed with a ‘STOP cassette’ 
composed of an array of four copies of the SV40 poly (A) addition site 242-244, 
which should halt transcription beyond the second intron (Figure 5.1B). 
Furthermore, introduction of the STOP cassette will also disrupt transcription of 
the POT1-55 allele, effectively knocking out both isoforms of POT1.  
Finally, given the lethality of deleting POT1a and -b in the mouse, we 
considered the likely cell lethal phenotype of cells lacking both alleles human 
POT1, which might be generated by TALENs (see Chapter 4). Therefore, 
HT1080 fibrosarcoma cells were first infected with a retrovirus containing cDNA 
encoding MYC-tagged full-length POT1 expressed from a CMV promoter (Figure 
5.1B), and the retrovirus also conferred hygromycin resistance. Because the 
POT1 rescuing allele is flanked with LoxP sites, exogenous POT1 can be excised 
by Cre recombinase after the endogenous POT1 loci have been targeted. 
Hygromycin resistant clones were isolated with the initial intent to use western 
blot analysis to determine whether the exogenously expressed POT1 could be 
efficiently deleted. However, the antibody used in previous studies 29 (that detects 
endogenous POT1-FL and POT1-55) 184 was no longer functional. Therefore a 
single clone, 20.3, was selected at random for further targeting. Eventual 
identification of a commercial antibody that was able to detect POT1-FL, but not 
POT1-55 (see Figure 5.1A), was used to determine that clone 20.3 expressed 
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exogenous POT1-FL at similar levels to endogenous POT1-FL, and could be 
effectively deleted upon treatment with Cre (Figure 5.2A-B). In addition, as shown 
previously 79, the levels of POT1 protein seem to be regulated such that 
overexpression of POT1 resulted in repression of protein production from the 
endogenous allele (see c20.3 in Figure 5.2B). 
A TALEN pair was designed to bind a site starting in intron 2-3 and 
extending into exon 3, such that the nuclease would not target the exogenous 
floxed POT1 cDNA. In addition, inclusion of the intron-exon junction near the 
predicted cleavage site enhances the likelihood of deleterious mutations that give 





Figure 5.1 TALEN-mediated inactivation of the gene for human POT1. (A) Schematic of the 
human POT1 locus, and the two reported isoforms and their respective ATGs. POT1-FL, full-
length POT1 protein; POT1-55, POT1 protein lacking the first OB fold. Exons not drawn to scale, 
coding exon numbers indicated (as annotated by Ensembl). Shading of exons corresponds to 
protein regions they encode. Known structures of and binding sites in POT1 are indicated. Navy 
line corresponds to peptide used to generate POT1 antibody used in this study (Abcam). (B) The 
POT1 locus, the targeting construct, and the resulting knockout allele. F1, R1, R2-PGK, R4-Zeo: 
PCR primers for genotyping. Arrows in bold: TALEN binding and cut sites. Schematic of MYC-
tagged hPOT1 cDNA with flanking LoxP sites (triangles), cloned into the pWZL retroviral vector 
(confers hygro resistance).  
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5.2.2 TALEN-mediated deletion of full-length human POT1 
HT1080 clone 20.3, expressing the floxed MYC-POT1 rescuing allele, was 
co-transfected with the aforementioned TALEN pair and the neomycin donor 
construct (Figure 5.1B). Cells were then selected with neomycin to enrich for 
POT1 alleles that had been targeted by the TALENs and repaired by HDR, 
resulting in deletion of exon 3 and acquisition of neomycin resistance. PCR 
analysis of neomycin resistant clones showed that 4 out of 34 (~12%) clones had 
integrated the donor cassette into one allele of POT1 (Figure 5.2B). Treatment of 
these heterozygous clones with Cre showed that 3 (c3, c5, c17) of the 4 clones 
expressed no detectable endogenous POT1-FL protein, which migrates slightly 
slower than the MYC-tagged POT1, suggesting bi-allelic disruption of the gene 
(Figure 5.2B). The efficiency of Cre-mediated deletion of POT1 varied between 
experiments (compare Figure 5.2A to 5.2B). Therefore, POT1-FL deletion was 
verified by immunoblotting for all experiments conducted, and only experiments 
that had less than 10% to undetectable levels of residual POT1 protein were 
analyzed.  
Sequencing of uninterrupted alleles in these heterozygous clones lacking 
endogenous POT1 revealed that clones c3, c5 and c17 all contained mutations 
close to the TALEN cut site (Figure 5.2C). Mutations had ablated POT1-FL by 
creating a frame-shift or a defect in splicing, indicating that errors generated 
during NHEJ-mediated repair of the TALEN-induced break had inactivated the 
second allele of POT1. However, these NHEJ-mediated mutated alleles lacked 
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integration of the STOP cassette and could still be transcriptionally active. 
Therefore, while these clones served as knockouts for full length POT1, the 
POT1-55 protein and potential exon skipping products generated by these 
mutated alleles might still be translated. Furthermore, POT1-55 and potential 
exon skipping products would not be detected by the POT1 antibody used in this 
study, as it recognizes an epitope in exon 4 that is absent from the predicted 
peptides (indicated in Figure 5.1A). RT-PCR with primers to exon 2 and exons 4, 
9, 13 and 15 was therefore performed to determine whether POT1-55 was being 
expressed. No products generated by exon skipping were detected, but products 
derived from the POT1-55 isoform were visible (Figure 5.2D). Therefore POT1-
FL cannot be generated from the endogenous POT1 locus in clones c3, c5 and 
c17, but POT1-55 is still transcribed and presumably translated in these clones. 
No product was amplified in two lanes of the RT-PCR (asterisks in Figure 5.2D), 
likely due to experimental error, as amplification from the cDNA was detected in 
other lanes.  
Telomeric ChIP on clone 17 (neo/mut) confirmed the loss of the 
exogenously expressed MYC-POT1 after the retroviral introduction of Cre 
recombinase, while levels of other shelterin components at telomeres were not 
affected (Figure 5.3A-B). Both control and targeted HT1080 clones exhibited 
slower growth when treated with Cre, presumably a consequence of Cre-induced 
DNA damage 245 (Figure 5.3C). The POT1-targeted clones had a mild 
proliferative defect, but did not cease proliferating. Immunoblotting of cells lacking 
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endogenous POT1-FL collected at four time-points during the growth curve, 
showed the reappearance of MYC-POT1 at approximately 6 days after Cre 
treatment (Figure 5.3C). The reappearance of MYC-POT1 was likely due to the 
outgrowth of some cells that escaped Cre infection. Retention of the exogenous 
allele of MYC-POT1 presumably provided these cells a proliferative advantage 
over POT1 null cells. Furthermore, MYC-POT1 was not detected at any time-
point after Cre infection in cells that had the wild type endogenous POT1 gene 
(Figure 5.3D). Taken together, these data suggested that POT1-deficiency 
challenged the cells. However, a puzzling aspect of the growth curve was that no 
plateau or trough was observed, which would be expected if POT1-deficient cells 
struggled to proliferate while POT1-proficient cells underwent enough population 
doublings (at least 6 PDs, if we assume 1% cells escaped Cre) to constitute 
majority of the culture. Moreover, at day 12 after ~10 PDs, MYC-POT1 
expressing cells had still not completely overtaken the culture, suggesting POT1-
deficient cells were still proliferating. At day 20 after Cre, complete repopulation 
of the culture by POT1-proficient cells was observed. Therefore, POT1-deficiency 
appears to be detrimental for cells; however from the data presented here, we 
cannot conclude that it is lethal.  
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Figure 5.2 Loss of POT1-FL in targeted clones. (A) Immunoblotting for POT1 (Abcam 
antibody) indicated that MYC-POT1 migrates more slowly than endogenous POT1, allowing us to 
distinguish between exogenous and endogenous forms of POT1. Bands corresponding to MYC-
POT1 and endogenous POT1 are indicated. Non-specific band serves as loading control; par, 
parental HT1080 population. (B) Top, PCR of neo resistant clones with F1, R1 and R2-PGK 
primers. Bottom, immunoblot of HT1080 clones with genotypes as indicated, before and 72 hours 
after treatment with Cre. Blot probed with anti-hPOT1 (Abcam). (C) Top, schematic illustrating 
TALEN binding sites, their predicted cutting site (grey arrows), the pyrimidine tract, splice 
acceptor (SA), and the location of coding exon 3 in the POT1 locus. Bottom, relevant sequences 
of the indicated clones. (D) RT-PCR on RNA from clones c5, c17 and the parental HT1080 cell 
line (par). Exons amplified as indicated. Bottom, expected sizes for the two known isoforms of 
POT1, and predicted sizes of potential products generated by exon skipping. Asterisks indicate 




Figure 5.3 Deficiency of POT1-FL is not tolerated. (A) Telomeric ChIP of targeted HT1080 c17 
with and without Cre treatment. Duplicate dot-blots were probed for telomeric or Alu repeats. (B) 
Average percentage of telomeric DNA recovered in ChIPs with the indicated antibodies (two 
independent experiments). Error bars: SEMs. (C) Growth curves of targeted and WT HT1080 
clones, plotted as cumulative population doublings over time (days) after Cre treatment as 
indicated. Genotypes of cell lines as indicated above. (D) hPOT1 (Abcam) immunoblot of cells in 
(C) at different time-points after Cre treatment as indicated.  
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5.2.3 Telomere deprotection in POT1-deficient cells 
Removal of full-length POT1 resulted in deprotected telomeres as 
revealed by the induction of a strong TIF response (~65%)(Figure 5.4A-B), 
similar to when mouse POT1a and –b are deleted (~75%) 31. Depletion of POT1-
FL and POT1-55 by shRNA results in only 40% of TIFs that occur in the G1 
phase of the cell cycle 184. It is not clear whether the lower level of TIFs is due to 
incomplete knockdown of POT1, or whether POT1-55 may contribute to TIF 
formation in the POT1-FL knockout cells (see Chapter 6). The cell cycle 
dependency of TIF formation in cells deficient for POT1-FL has not yet been 
tested, however, considering 65% of cells were TIF positive, it is likely that TIFs 
persist through most of the cell cycle. DNA damage signaling remained 
repressed in clones 20.3 (homozygous for WT POT1) and c21 (heterozygous for 
WT POT1), indicating that one allele of POT1 is sufficient to inhibit DNA damage 
signaling at telomeres (Figure 5.4B), consistent with previous observations 
showing that POT1a and POT1b are haplosufficient 31. A partial, but significant 
reduction of TIFs is observed when POT1 is depleted by shRNA in ATR-deficient 
HCT116 cells or MEFs 148. Treatment with an ATR inhibitor almost entirely 
repressed the occurrence of TIFs in the POT1-deficient c17 clone, confirming 
that human POT1-FL is required to repress activation of the ATR kinase at 
telomeres (Figure 5.4B). 
Metaphase spreads of cells lacking POT1-FL showed no gross 
chromosomal aberrations. An increase in telomere sister associations was 
 113 
observed (Figure 5.4C-E), which also occurs upon deletion of mouse POT1a and 
-b 31. Metaphase spreads also showed several chromosome ends lacking one 
(sister loss) or two (signal free ends) telomeric signals. However, this was likely 
due to difficulty in detection of these telomeres by FISH, as WT cells showed the 
same phenotype (Figure 5.4D). There was no significant induction of NHEJ at the 
telomeres lacking POT1, as evidenced by the lack of telomere fusions (Figure 
5.4E). Fragile telomeres, a readout for telomere replication problems 156, are not 
observed at telomeres lacking POT1a/b, and have not yet been assessed in this 
study31. The propensity of POT1-deficient cells to undergo HDR was complicated 
to test for two reasons. First, due to the short telomeres of HT1080 cells, the 
telomeric fluorescent signals are weak, making the analysis of CO-FISH difficult. 
Second, telomere recombination in MEFs lacking POT1a and –b is observed only 
when Ku is also absent. However, since Ku-deficiency is lethal in human cells, 
we were unable to co-delete Ku and POT1 240,241.  
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Figure 5.4 ATR-dependent DNA damage signaling induced upon loss of full-length POT1. 
(A) TIF assay on HT1080 c17 before and after deletion of POT1 with Cre. Green, telomeric FISH; 
red, IF for 53BP1; blue, DNA (DAPI). (B) Quantification of TIFs assay as in (A). TIF analysis was 
performed on three cell lines 36 and 72 hours after treatment with Cre. ATR inhibitor ETP-46464 
254 was added to indicated cells 48 hours after Cre treatment at a final concentration of 1μM, for 
24 hours. Values represent mean from three independent experiments with SDs. Calculations of 
significance based on paired two-tailed Student’s T-Test (C) Metaphase spreads of c17 cell line 
before and after treatment with Cre as indicated. White arrows point to examples of telomeric 
‘sister associations’. (D) Aberrant features of metaphase spreads as in (C) were scored. Values 
represent mean of two independent experiments, where > 400 chromosomes were scored. Error 
bars: SEM. (E) Table showing occurrence of telomere fusions as detected in (C).  
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5.2.4 Maintenance of telomere overhangs 
Removal of both mouse POT1 proteins (or POT1b alone) results in 
extended 3’ telomere overhangs 31,52,150, whereas knockdown of human POT1-
FL, but not POT1-55, leads to a reduction in overhang signal 184,185. Expressing 
mutant alleles of POT1a or POT1b that lack their first OB fold, similar to POT1-
55, results in increased overhang signals, presumably due to displacement of 
endogenous POT1a/b by competing for binding to TPP1 246. Interestingly, the 
amount of single-stranded DNA at chromosome ends was unchanged upon loss 
of POT1-FL (Figure 5.5A-B) based on detection of the single-stranded telomeric 
DNA by in-gel hybridization of a labeled C-strand telomeric repeat probe to native 
telomeric restriction fragments. The E. coli 3’ exonuclease, ExoI, was used to 
confirm that the detected signal was derived from terminal 3’ overhangs (Figure 
5.5A). Despite observing increased overhangs in the presence of DNA damage 
signaling in the POT1a/b double knockout MEFs 31, we considered the possibility 
that the DDR response at human telomeres interferes with overhang processing. 
However, treatment with an ATR inhibitor to repress DNA damage signaling at 
deprotected telomeres in POT1-deficient cells showed no change in the telomere 
overhang signals (Figure 5.5C-D).    
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Figure 5.5 No change in 3’ telomere overhangs upon loss of POT1-FL. (A) Overhang 
analysis of clones lacking functional endogenous POT1 loci, before and after removal of 
exogenous POT1 with Cre as indicated. Left, in-gel detection of native telomeric restriction 
fragments with a C-strand telomeric probe revealing the G-strand overhang signals; right, same 
gel rehybridized after in situ denaturation of the DNA, revealing the total telomeric DNA in each 
lane. Samples were treated with ExoI (Exonuclease I) as indicated. (B) Overhang signals from (A) 
were normalized to total telomeric signals in each lane and plotted as a ratio compared to the WT 
overhang signal of the corresponding cell line, labeled as ref. Values plotted for clones c5 and c3 
are from one experiment. Value plotted for c17 is the mean of 3 independent experiments with 
SD. Lack of statistical significance derived from two-tailed paired t-test. (C) Overhang analysis of 
clones with indicated genotypes, Cre treatment and ATR treatment as described in Figure 5.4B. 
Detection of native (left) and denatured (right) telomeric restriction fragments as described in (A). 
(D) Quantification of overhang signals in (C) using the same methodology as in (B). Values 
represent means of three independent experiments with SDs. Lack of statistical significance 
derived from two-tailed paired t-test.   
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Mouse POT1b recruits CST to telomeres, presumably to perform fill-in 
synthesis 52. Human POT1 interacts with CST 247,248 and may serve a similar 
function of recruitment. As a positive control for alterations in overhang 
maintenance, we examined the effect of a mutant of POT1 (S322L), proposed to 
disrupt the POT1-CST interaction and result in extended overhangs (Hiro Takai, 
unpubl.). FLAG-tagged constructs of wild type POT1 or the mutant POT1-S322L 
were retrovirally expressed in clones c5 and c17 (Figure 5.6A). Overhang 
analysis showed that expression of POT1-S322L in cells lacking POT1-FL indeed 
resulted in an increase in overhang signal (Figure 5.6B-C), perhaps due to the 
lack of CST-mediated fill-in. Although this positive control showed that the effects 
of POT1 on overhang maintenance could be detected in these clones, it remains 
puzzling that there is no overhang phenotype upon the deletion of POT1. POT1 
might therefore be required to both stimulate resection and regulate CST 
mediated fill-in to obtain the correct overhang length.  
Partial knockdown of POT1-55 yields no overhang phenotype, and shRNA 
targeting both POT1-FL and POT1-55 shows no additive change in overhang 
signal as compared to depletion of POT1-FL alone 184. To confirm that POT1-55 
does not play a role in overhang maintenance, clone c21 (heterozygous for WT 
POT1) was subjected to a second round of targeting with TALENs and the 
blasticidin or zeocin donor constructs. Blasticidin and zeocin resistant clones 
were screened by PCR to identify clones where both alleles of POT1 had been 
targeted (Figure 5.7A). RT-PCR of homozygous targeted clones confirmed the 
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lack of the POT1-55 isoform mRNA, while it was still present in clone c17, which 
had a single-integration of the STOP cassette (Figure 5.7B). Similar to the earlier 
observation that endogenous POT1-FL was repressed upon overexpression of 
MYC-POT1 (Figure 5.3D), detection of the POT1-55 isoform by RT-PCR was 
enhanced after removal of MYC-POT1 with Cre treatment (Figure 5.7B). 
Therefore, regulation of POT1 protein levels might be mediated by up- or down-
regulation of transcription, as opposed to proteasome-mediated degradation, but 
the mechanism of how this occurs is unknown. However, multiple RT-PCR 
replicates need to be performed to confirm this finding of potential crosstalk 
between protein levels of POT1 and transcription of its locus.  
POT1-FL was also still detected by RT-PCR after Cre treatment, albeit at 
much lower levels (Figure 5.7B), probably due to a low percentage of cells that 
had not completely deleted the exogenous MYC-POT1 rescue allele. Quantitative 
RT-PCR showed that expression of POT1-FL was significantly attenuated after 
treatment with Cre (Figure 5.7C), and was confirmed by immunoblotting (Figure 
5.7D). Overhang analysis of clones lacking both isoforms of POT1 showed no 
change in overhang signal, indicating that POT1-55 did not contribute to 
overhang maintenance.  
A recurrent phenotype that was observed on these overhang gels was 
mild telomere elongation after deletion of POT1-FL (Figure 5.5A, Figure 5.6B, 
Figure 5.7E). Given the role of POT1 in the negative regulation of telomerase 
29,79,249, this lengthening could be due to the action of telomerase. Interestingly, 
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telomere elongation was not observed after deletion of both POT1-FL and POT1-
55 (Figure 5.7E), which would suggest that telomere extension is mediated by 
POT1-55 when POT1-FL is deleted. Additional replicates need to be performed 






Figure 5.6 Extended overhangs in POT1-deficient cells expressing the S322L mutant.  
(A) Immunoblot for FLAG and hPOT1 in clones expressing FLAG-POT1-FL (WT), FLAG-POT1-
S322L (S322L) or vector control. Treatment with Cre (as indicated) removes expression of MYC-
POT1-FL, which all cell lines also express. n.s., non-specific band detected by the antibody 
serves as a loading control. (B) Gel for overhang analysis as previously described in Figure 5.5A. 
Cre treatment and ExoI treatment as indicated. Left, native gel; Right, denatured gel. wt, FLAG-
POT-FL; m, FLAG-POT1-S322L; v, vector control. (C) Quantification of overhang signals in (B). 
Native signals were normalized against denatured signals in the corresponding lanes and plotted 
as a ratio compared to the signal in the WT sample for each cell line, labeled as ref. Values 




Figure 5.7 No change in 3’ telomere overhangs upon deletion of both POT1 isoforms.  
(A) Genotyping PCR of zeocin (left) and blasticidin (right) resistant clones. Top, PCR with primers 
F1, R1, and R2-PGK. Loss of WT allele indicates successful targeting. Bottom, PCR with primers 
F1, R1 and R4-Zeo. Appearance of top band and disappearance of bottom band confirms 
successful targeting. Genotypes of successfully targeted clones indicated below. (B) RT-PCR 
detecting POT1-FL and POT-55. 4-fold serial dilutions of reverse transcribed cDNA were used for 
PCR reactions. (C) qRT-PCR of POT1-FL in two clones before and 60 hours after expression of 
Cre. (D) Immunoblot showing deletion of POT1-FL in two clones at 60 or 96 hours after Cre 
expression. Genotypes as indicated. Non-specific band serves as loading control. (E) Gel for 
overhang analysis of clones lacking POT1-FL or both POT1-FL and POT1-55. Genotypes and cre 
treatment as indicated. Quantification of the gel shown below where overhang signals were 
normalized to total telomeric signals in each lane and listed as a ratio compared to the WT 
overhang signal of the corresponding cell line. WT overhang signals set to 1 are in bold with a 
larger font. 
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5.3 Summary of findings 
Human POT1-FL, consistent with prior data 148, is required to inhibit ATR-
dependent DNA damage signaling at telomeres. Whether POT1-55 functions as 
a dominant-negative allele exacerbating the occurrence of TIFs remains to be 
determined, as does the cell cycle dependence of TIF formation in POT1-FL 
knockout cells. Deprotected telomeres in POT1-FL-deficient cells were not 
vulnerable to NHEJ, as deduced by the lack of telomere fusions observed in 
these cells. However, an induction of telomere sister associations was noted in 
cells lacking POT1, but the molecular basis of these associations is not known.  
Surprisingly, unlike mouse POT1a/b-deficiency 31, human cells lacking 
POT1 did not show a change in overhang status. The underlying cause of this 
discrepancy is not clear, and many options remain to be tested (discussed further 
in Chapter 6). Briefly, it is possible that POT1 is required to promote both 
resection, and CST-mediated fill-in synthesis, thereby resulting in no overall 
change in overhang signal when POT1 is deleted. Alternatively, removal of POT1 
could allow telomerase to extend the overhang, and CST could be recruited to 
perform fill-in synthesis independently of POT1, leaving no net change in 
overhang lengths. Finally, although it seems unlikely, it is possible that steps 
upstream of ATR signaling, such as RPA loading on ssDNA play a role in 
overhang regulation. 
The conditional knockout system we have generated in human cells will be 
of great use, not only to understand the functions of human POT1, but also as a 
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means to mechanistically evaluate numerous mutations recently identified in 
POT1 in various cancers 250-253 (see Chapter 6). One caveat of our system is the 
incomplete Cre-mediated deletion. One possible solution is to use a retroviral Cre 
that confers puromycin resistance and select for Cre-expressing cells. An option 
for future targeting strategies is to flank both the exogenously expressed cDNA 
and the hygromycin cassette with LoxP sites, such that cells are rendered 
sensitive to hyrgomycin upon treatment with Cre, and hygromycin selection can 
be retained to select for other constructs of interest. 
Lastly, the POT1-55 knockout cell lines described in this chapter may be 
used to gain insight into the purpose of POT1-55. While the delineation of 
functions that mouse POT1a and –b perform is evident, it remains unclear why 
the POT1-55 isoform of human POT1 exists. It is difficult to hypothesize about 
potential roles of POT1-55 in the maintenance of telomere integrity, as it 
resembles a dominant negative mutant, is weakly expressed and removal of 
POT1-55 displays no apparent phenotype.   
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Chapter 6: Discussion 
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6.1 The role of mammalian Rap1 
Analysis of mouse knockouts and TALEN-mediated human knockouts of 
Rap1 reveal that, unlike its yeast counterparts, mammalian Rap1 is not required 
for cellular and organismal viability, does not play a major role in telomere length 
regulation, and is largely dispensable for telomere protection. Loss of Rap1 does 
not affect the other components of shelterin, the modification of telomeric 
histones, the synthesis of TERRA, or the maintenance of the 3’ telomeric 
overhang. Telomeres lacking Rap1 do not show consistent changes in their 
length, do not activate the DNA damage response, or become processed by 
NHEJ. However, we did find that mouse Rap1 is required to repress HDR at 
telomeres redundantly with Ku70/80, a function we were unable to test in human 
cells due to lethality ensuing deletion of Ku70 or -80. Remarkably, we observed 
that human Rap1, like its mouse and unicellular orthologs, affects gene 
expression. Therefore, we propose that the conservation of Rap1 reflects its role 
in transcriptional regulation, rather than a function at telomeres. 
The dispensability of Rap1 in telomere end-protection was especially 
surprising with regard to previous reports implicating mammalian Rap1 as a 
repressor of NHEJ 213 160. An in vitro end-joining reaction with linear telomeric 
substrates could be repressed by addition of the Rap1/TRF2 complex, but not 
Rap1 or TRF2 alone 213. Perhaps the better binding affinity of TRF2/Rap1 to 
duplex telomere substrates, than that of TRF2 (Chapter 3 and 235), allowed for 
more efficient inhibition of NHEJ. An in vivo study shows Rap1 can be tethered to 
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HeLa telomeres by being fused to the DNA binding domain of a S. pombe protein 
that preferentially binds TTAGGG repeats (TebDB) 160. Removal of endogenous 
Rap1/TRF2 by a dominant negative mutant results in fusions, which can be 
repressed by Rap1ΔCT-TebDB. Repression of NHEJ is not conferred by TebDB 
itself, however, it is possible that Rap1ΔCT-TebDB acts as a neomorph. The 
DNA-binding affinity of Rap1ΔCT-TebDB or its placement at telomeres may 
physically occlude access of DNA repair factors. Alternatively, it is possible that 
Rap1 plays a redundant role in the repression of telomere fusions in the absence 
of TRF2, however our preliminary data does not support this hypothesis. In 
addition, this setting of Rap1 at telomeres lacking TRF2 is highly unlikely to 
naturally occur, due to the requisite binding of Rap1 to TRF2 for maintenance of 
Rap1 protein levels and telomeric localization.  
6.1.1 Rap1 – a conserved telomeric protein with non-telomeric functions 
Several lines of evidence indicate that Rap1 is a highly conserved 
component of mammalian shelterin. The human gene encoding Rap1 has 
diverged little from its chimpanzee counterpart (1 base change/100 codons; 0.25 
amino acid (aa) changes/100 aa), whereas the genes for other shelterin 
components show much greater divergence (e.g., 3.6, 2.4, and 1.7 base 
changes/100 codons and 2.2, 1.1, and 0.65 aa changes/100 aa for TRF2, TRF1, 
and TIN2, respectively). Human and chimpanzee sequence was compared as 
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these sequences align most closely and allow for more accurate comparison of 
changes in nucleotide and amino acid sequence between shelterin proteins.  
Data from the Exome Variant Server (NHLBI GO Exome Sequencing 
Project, Seattle, WA (URL: http://evs.gs.washington.edu/EVS/) [as of 02/2015]) 
identifies only 14 potentially deleterious (splice, nonsense, frame-shift or 
missense) mutations in Rap1 in ~13,000 alleles sequenced. Compared to Rap1, 
a larger number of potentially deleterious mutations have been identified in all 
other shelterin components (19, 22, 50, 49 and 24 for TRF2, TRF1, TIN2, TPP1 
and POT1, respectively).  
Assessment of a gene damage index (GDI) derived from the 1000 
Genomes Project 255, which reports on the cumulative mutational damage in a 
given human coding gene, places Rap1 in the top 20% of human genes with 
regard to tolerance to mutation intolerance (Y. Itan, pers. comm.). In addition, 
Rap1 ranks among the top 10% of coding human genes in terms of ‘functional 
indispensability’, a characteristic that incorporates gene centrality (based on 
interaction data pooled from various biological systems), structural information, 
and evolutionary constraints 256. In this regard, only TIN2 scores higher than 
Rap1, as expected based on its multiple interaction interfaces in shelterin. The 
aforementioned estimates of gene conservation do not necessarily highlight 
essential genes, instead they aim to identify genes in which mutations may lead 
to disease phenotypes. Furthermore, it is possible that Rap1 may serve an 
important function in a specific tissue or cell type that we did not test, which may 
explain the selective pressure placed upon Rap1.  
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The level of conservation of Rap1 raises the question: what functional 
aspect of Rap1 is under selective pressure? The repression of HDR is unlikely to 
explain the conservation of Rap1, since the HDR phenotype only manifests itself 
when Ku70/80 are absent. It is also unlikely that Rap1 has a tissue specific role 
at telomeres, given that mice lacking Rap1 are alive and largely normal, and our 
demonstration that Rap1 deletion from human cell lines originating from different 
tissues show no overt telomere phenotype. The conservation of Rap1 is also not 
explained by a role in meiosis since the Rap1 knockout mice are fertile and, 
unlike yeast lacking Rap1, form a normal meiotic bouquet 19,36,217,218,257,258. It is 
not excluded that Rap1 has (as yet unknown) multiple interactions within 
shelterin or with shelterin-associated factors that explain its conservation, or 
alternatively, that its role at telomeres is redundant. We favor the idea that the 
conservation of Rap1 is due to its role in transcriptional regulation 220-223,259 where 
it may have multiple distinct interaction partners that constrain its evolution.  
Given that mammalian Rap1 is unlikely to bind directly to DNA 20,193, and 
that the majority of the chromosome-internal Rap1-associated loci are devoid of 
telomeric sequence 220,223, it is expected that interacting factors recruit Rap1 to 
these sites. In fact, complementation of Rap1-deficient MEFs with the Rap1 
I312R allele (deficient in TRF2-binding), restores transcriptional regulation of 
~85% of genes 221, consistent with the idea that Rap1 has binding partners that 
target Rap1 to these loci in a TRF2-independent manner. Identification of these 
factors could potentially illuminate (as yet undefined) telomere functions of Rap1. 
 129 
Rap1 potentially evades being targeted for degradation by binding to 
TRF2 (Chapter 3), which is puzzling when trying to understand how Rap1 
regulates transcription independently of TRF2. One possibility is that other 
binding partners are able to protect Rap1 from degradation. However, the nearly 
undetectable levels of Rap1 in TRF2-depleted cells 19,22,24, suggest that very low 
amounts of Rap1 would be bound to and protected by other factors. It would 
therefore be of interest to determine whether this residual non-telomeric Rap1 is 
sufficient for transcriptional regulation.  
6.1.2 Rationale for retention of Rap1 at telomeres  
If Rap is conserved due to its role in transcriptional regulation, this begs 
the question why its interaction with TRF2 and localization to telomeres is 
retained. One possibility is that TRF2 is required for Rap1 to localize to some of 
the chromosomal loci that it transcriptionally regulates. The aforementioned 
study221 shows that ~15% of transcriptional regulation by Rap1 is dependent on 
its interaction with TRF2. In addition, ~15% of loci associated with human Rap1 
also contain the consensus sequence for TRF2-binding 223.  
Another possibility is that telomere length influences the transcriptional 
control performed by Rap1. Telomere shortening may result in displaced 
Rap1/TRF2 complexes, which can then bind to additional chromosome-internal 
sites. Several studies in human cells show that telomere shortening, prior to the 
induction of DNA damage signaling (as detected by TIF assays), can affect 
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expression of genes located both proximal 260,261 and distal 262 to telomeres. Hi-C 
(chromosome capture followed by high throughput sequencing) reveals that 
chromosome looping can place telomeres adjacent to genes located up to 10 Mb 
away 262, which could potentially be another mode of Rap1 recruitment to loci that 
it regulates. Moreover, both up- and down-regulation of transcripts are observed 
following telomere shortening 262, suggesting that gene expression does not 
seem to be inhibited by proximity to heterochromatic telomeric chromatin. 
Instead, it is more likely to be modulated by a transcription factor, similar to our 
observations of Rap1 function in both up- and down-regulation of gene 
expression.  
It is unclear why telomere length should play a role in the control of gene 
expression. One possibility is that telomere shortening may initiate a 
transcriptional program that promotes entry into senescence. In S. cerevisiae, 
when critical telomere shortening is induced by deletion of telomerase (tlc1Δ), 
Rap1 relocalizes to hundreds of new target genes 263. Redistribution of Rap1 in 
yeast during the onset of senescence is dependent on Mec1 (the ATR homolog), 
suggesting DNA damage also plays a role in Rap1 relocalization. DNA damage 
signaling is not reported to accompany the gene expression changes observed 
upon telomere shortening in human cells, which may suggest that other signals 
promote senescence in mammalian cells. Alternatively, the TIF assay is not the 
most sensitive method to evaluate DNA damage signaling and may miss low 
frequency events that are responsible for triggering this change in cell state. It will 
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be interesting to see if mammalian Rap1 is required to initiate a transcriptional 
program based on changes in telomere length. 
6.1.3 No Rap1 ortholog in Drosophila 
Drosophila telomeres, while serving the universal function of maintaining 
chromosomal integrity, lack many hallmarks of eukaryotic telomere structure and 
maintenance. For instance, Drosophila species lack telomerase, maintaining their 
telomeres by specialized retrotransposons instead, and they also have variable 
telomere repeats and sequence at their termini (reviewed in 285). Furthermore, 
standard BLAST (Basic Local Alignment Search Tool) searches have revealed 
no homologs of the shelterin components in Drosophila 286, while most non-
telomeric human proteins have Drosophila homologs. In consideration of the non-
telomeric role of Rap1, the selective pressure Rap1 appears to be under, and the 
advances in annotated sequence databases, we reexamined whether Rap1 
could be identified in flies. Due to the low sequence conservation of Rap1, we 
used PSI-BLAST (Position-Specific Iterative), which derives a position-specific 
scoring matrix that allows for detection of distant relationships between proteins. 
Consistent with previous reports, PSI-BLAST of the conserved BRCT and MYB 
domains of Rap1 revealed no related homologs in the Diptera order, suggesting 
that other proteins may have evolved to become functional analogs of Rap1 in 
flies. 
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6.2 The mechanism of HDR repression at telomeres 
How mouse Rap1 represses HDR at telomeres when Ku70 is absent 
remains to be determined. The data in Chapter 3, showing that Rap1 when 
tethered to TRF1 fails to repress HDR, while negative, would suggest a 
requirement for Rap1/TRF2 complex formation in the inhibition of HDR. One 
possibility is that the complex might interact with a factor that represses HDR that 
Rap1 alone or TRF2 alone do not interact with. Two-hybrid and mass 
spectrometry have identified numerous protein complexes bound to Rap1 and/or 
TRF2 21,78,225,264-266, but have not pinpointed a factor that could inhibit HDR. 
However, these experiments were not carried out in a setting where HDR is 
unleashed. Pull-down of TRF2/Rap1-associated proteins in Rap1F/FKu70-/- MEFs 
(where HDR is repressed), followed by elimination of factors that remain 
associated to TRF2 in a pull-down after Cre treatment (where HDR is induced), 
might nominate candidates for such HDR repressing factors. 
Alternatively, experiments described in Chapter 3 and aforementioned 
studies 235,236 show that Rap1 can alter the DNA-binding activity of TRF2, but it is 
unclear whether this is relevant to HDR inhibition (see below, section 6.2.1). In 
addition, it is possible that Rap1, TRF2, and POT1a/b act together to repress 
HDR (see below, section 6.2.2). 
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6.2.1 The effect of Rap1 on the DNA-binding activity of TRF2 
Our initial hypothesis was that Rap1 might promote binding of TRF2 to 
specific telomere structures that are reminiscent of substrates for HDR, such as 
the ds-ss transition at the telomere terminus. Doing so would presumably prevent 
loading of HDR factors, such as BRCA2 and Rad51, which are required for 
repair. Arat and Griffith 235 observed that Rap1/TRF2 binds better to a ds-ss 
telomere junction than a duplex telomere template. However, we, and Januskova 
et al. did not observe this difference. The conflicting results may be due to 
methods of protein purification and/or use of different substrates for the gel-shift 
assays. Preliminary gel-filtration chromatography revealed various 
oligomerization states within our purified proteins, which could affect their 
efficiency of DNA-binding. Therefore, careful characterization of DNA binding 
activities of TRF2 and Rap1/TRF2 to various telomere substrates needs to be 
conducted with homogenous protein populations. Additionally, these DNA-
binding studies also need to be performed in the context of the entire shelterin 
complex, as POT1 binding to ssDNA may affect the binding affinity of Rap1/TRF2 
to the ds-ss junction.  
Insight into the mechanism of HDR repression by Rap1/TRF2 could also 
be acquired by performing a displacement loop (D-loop) assay. Here, in the 
presence of ATP (and Rad54 to stabilize filament formation and D-loops 267), 
Rad51 polymerizes on a radiolabeled ssDNA probe, which contains 
complementary sequence to one strand of unlabeled supercoiled duplex DNA. 
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Strand invasion events where the ssDNA probe displaces one strand of duplex 
DNA can be detected by a shift in the migration of the ssDNA probe on an 
agarose gel 268. To determine whether Rap1/TRF2 inhibits HDR by preventing 
strand invasion, the d-loop assay could be modified to use telomere-repeat 
sequences and compare the ability of TRF2 and Rap1/TRF2 to inhibit strand 
invasion. 
6.2.2 Rap1, TRF2 and POT1 may work together to repress HDR 
Data shown in Chapter 3 suggests that mouse Rap1/TRF2 and POT1a or 
–b may act together to inhibit HDR at telomeres. POT1a and -b were removed 
from telomeres in Rap1F/FKu70-/- MEFs by treatment with an shRNA targeting 
TPP1 (shTPP1). 10% of T-SCEs were observed on average when both POT1a/b 
were removed by shTPP1, or when Rap1 was deleted with Cre. No additive 
incidence of T-SCEs was detected when all three shelterin components (Rap1, 
POT1a and POT1b) were removed, suggesting they were epistatic in their 
repression of HDR. In contrast to these results, deletion of mouse TPP1, which 
phenocopies POT1a/b-deficiency, did not lead to induction of T-SCEs in a Ku70-
deficient background (T. Kibe, unpubl.). Furthermore, deletion of TIN2, which 
also largely phenocopies POT1a/b-deletion, did not lead to induction of T-SCEs 
in the context of Ku70-deficiency (K. Takai, unpubl.).  
One explanation to reconcile the results described above could be the 
time it takes for these MEFs to become immortalized. As discussed in Chapter 3, 
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Ku70-/- MEFs rapidly downregulate HDR at telomeres through an undefined 
mechanism. MEFs isolated from Ku-deficient embryos tend to have difficulty 
proliferating and immortalization times can vary significantly. Therefore, it is 
possible HDR was assessed too late in the TPP1/Ku70- and TIN2/Ku70-deficient 
MEFs. Isolation and immortalization of Rap1F/FKu70-/- and TPP1F/FKu70-/- MEFs 
in parallel would allow for a more accurate analysis of T-SCE frequencies. 
Alternatively, the TPP1sh could have off-target effects leading to the appearance 
of T-SCEs, which could easily be tested by treating TPP1F/FKu70-/- MEFs with the 
TPP1sh and assessing induction of T-SCEs.  
The lack of T-SCEs in TPP1/Ku70- and TIN2/Ku70-deficient MEFs does 
not necessarily argue against the idea that POT1a/b may still act together with 
Rap1/TRF2 to repress T-SCEs. As discussed previously, POT1 can interact with 
TRF2 21,152,185,234 and repression of HDR by POT1 may therefore be independent 
of its TIN2/TPP1-mediated recruitment to telomeres. 
6.2.3 What is the telomeric substrate for HDR? 
Detection of T-SCEs serve as our readout for HDR taking place at 
telomeres, however this assay does not report on the source of HDR initiation. 
Most of our studies have focused on the ds-ss telomere terminus as a structure 
vulnerable to HDR. Another source of telomeric HDR substrates could arise from 
replication errors. For instance, HDR is involved in restarting collapsed replication 
forks or bypassing a lesion encountered during replication (reviewed in 269). Our 
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preliminary analysis of MEFs lacking TRF1 (required to facilitate telomere 
replication) and Ku80 showed an induction of T-SCEs, suggesting that telomeres 
are also vulnerable to HDR during DNA synthesis. Therefore numerous telomere 
configurations are likely to be vulnerable to HDR and further investigation into the 
mechanism of HDR, especially biochemical approaches, will need to take this 
into account.  
6.2.4 Ku70/80-deficient cells adapt to recover repression of HDR 
The downregulation of HDR at telomeres in late-passage Ku70-/- MEFs 
was an intriguing finding, supporting the notion that HDR is stringently regulated 
(reviewed in 270), and warrants further investigation. First, it will be of interest to 
determine whether this down-regulation of HDR is global or telomere-specific. 
Assessment of global HDR using the DR-GFP assay designed in the Jasin lab 
171,271 proved to be difficult due to the low rate of targeted genomic integrations in 
MEFs, as well as variable transfection efficiencies and cell survival post 
transfection. The DR-GFP reporter construct contains one copy of GFP that has 
been rendered dysfunctional (due to the insertion of an I-SceI site), and a donor 
partial GFP sequence. Induction of a DSB by transfection of the I-SceI 
endonuclease, and repair by HDR using the donor GFP template restores GFP 
expression. Optimal use of this assay involves integration of a single copy of the 
reporter into the HPRT locus to remove confounding effects from location of and 
multiple copy integration. Recent developments in genome editing using 
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CRISPR-Cas9 based technologies might now allow for efficient targeting of the 
DR-GFP construct into MEFs and determine global recombination levels in late-
passage Ku70 deficient MEFs.  
Secondly, identification of factors that perform this inhibition of HDR will be 
interesting as they may illuminate aspects of HDR regulation that are as yet 
unknown. A preliminary microarray to assess gene expression changes in early- 
and late-passage Ku70-deficient MEFs yielded a list of 64 significantly 
deregulated genes. Additional microarrays using multiple Ku70-deficient cell lines 
need to be performed to see if the same hits are generated. In addition, analysis 
of gene expression changes in early- and late-passage Ku-proficient cells will 
assist in eliminating candidate genes that are artifacts due to long-term tissue 
culture.  
Lastly, the finding that Ku70-deficient MEFs down-regulate HDR in culture, 
raises the question of whether other processes adapting to Ku70-deficiency 
occur during embryogenesis. A notable difference between mouse and human 
Ku70/80 is that acute deletion of Ku70 or Ku80 in human somatic HCT116 cells 
results in lethality and massive telomere recombination 240,241,272, while mice 
lacking Ku70 or Ku80 are alive and fertile, albeit smaller and showing defects in 
DNA repair 113,273. Development of conditional mouse knockouts of Ku 
components should be informative to investigate whether acute deletion of Ku 
from mouse somatic cells has similar effects as those reported in human cells.   
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6.3 Investigating the role(s) of human POT1 
We describe the generation of conditional TALEN-mediated human 
knockouts of POT1-FL and double knockouts of POT1-FL/POT1-55. Due to a 
small percentage of cells that consistently escape Cre-mediated deletion of 
POT1-FL, the potential cellular lethality of human POT1 knockouts cannot be 
conclusively determined. Our current system provides a timeframe of 3-6 days 
within which to assess telomere phenotypes of POT1-deficiency, comparable to 
the approach undertaken for investigation of mouse POT1 proteins.  
6.3.1 Functions of POT1 in telomere end-protection 
Deletion of full-length human POT1 induces an ATR-dependent TIF 
response (~65%), similar to mouse cells lacking POT1a/b (~75%) 31,148. 
Incomplete knockdown of human POT1 with shRNAs may explain the 
intermediate TIF response (~40%) observed in a previous study 184. Alternatively, 
it is possible that the presence of POT1-55 in cells lacking POT1-FL contributes 
to the additional induction of TIFs. The rationale for this explanation is derived 
from phenotypes of the dominant-negative alleles of POT1a and –b that lack their 
first OB fold, akin to human POT1-55. Overexpression of POT1aΔOB or 
POT1bΔOB results in a moderate induction of TIFs (~25%), presumably by 
displacing endogenous POT1a/b 246. No dominant-negative phenotype is 
observed prior to deletion of POT1-FL, likely due to the 10-fold lower expression 
of POT1-55 184, placing it at a disadvantage to compete with POT1-FL for binding 
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to TPP1 and telomeric recruitment. Analysis of TIFs in the double knockout 
POT1-FL/POT1-55 will reveal whether POT1-55 acts as a dominant-negative in 
the absence of POT1-FL. It is not clear why telomeres are most vulnerable to 
DNA damage signaling during G1, when POT1 is depleted by shRNAs 184. Given 
that 65% of cells lacking POT1-FL are TIF-positive, it is likely that TIFs persist 
through most of the cell cycle. However, cell-cycle analysis needs to be 
performed to confirm normal phase distribution. 
Despite the telomere deprotection induced upon loss of POT1-FL, 
telomeres do not appear to succumb to NHEJ. NHEJ is also largely repressed at 
telomeres depleted for POT1 with siRNA or shRNA, which show a very low 
incidence of telomere fusions (~0.1%) 184,185. However, 2% of chromosome 
fusions are detected in POT1a and –b knockout MEFs 31. Taking into account the 
low frequency of chromosome fusions and the few experimental replicates 
analyzed, additional assessment is required to determine whether this difference 
is significant. 
Deletion of human POT1-FL and mouse POT1 proteins leads to induction 
of telomere sister associations, where 8% and 1.4% 31 of telomeres engage in 
sister associations, respectively. The frequency of these events seem to vary 
between cell lines 159, as basal levels of telomere sister associations in the 
human and mouse cell lines prior to Cre infection are 4% and 0% 31, respectively. 
The telomere sister associations are not a result of NHEJ 156. Instead, low 
frequencies of telomere sister associations occur in settings where ATR is 
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activated 159, and robust induction of this phenotype is observed when telomeres 
encounter replication problems 156. Based on the low induction (2-fold) of 
telomere sister associations in cells lacking POT1-FL, we do not expect to 
observe a fragile telomere phenotype, but this remains to be confirmed. 
Telomere sister associations are likely due to non-covalent interactions, such as 
strand invasion, but the exact molecular basis of these events and their 
consequences for telomere integrity remain unknown.    
6.3.2 Telomere length regulation by POT1-55  
An interesting observation shown in Chapter 5 is the slight increase of 
telomere length in cells lacking POT1-FL, which is not detected upon loss of 
POT1-FL/POT1-55. A mutant allele of human POT1 that lacks its first OB fold 
(POT1ΔOB) 79 induces extreme telomere lengthening when overexpressed in 
HTC75 cells, presumably through a similar mechanism as described before, 
involving displacement of endogenous POT1 and loss of telomerase inhibition. 
Similar to POT1ΔOB, POT1-55 may be responsible for the lengthening of 
telomeres observed upon deletion of POT1-FL. However, depletion of POT1 with 
siRNA also resulted in telomere elongation 29, therefore it is unclear why a setting 
lacking both isoforms of human POT1 would not show telomere lengthening. 
Since the experiment has only been conducted once, it is possible that 
subsequent repetitions will show a telomere elongation phenotype. Additionally, if 
treatment of cells lacking POT1-FL or POT1-FL/POT1-55 with a telomerase 
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inhibitor abolishes the observed increase in telomere length, this would confirm 
that loss of POT1 allows telomerase access to telomeres.  
The raison d’être of POT1-55 remains unclear. Low levels of POT1-55 
protein suggest POT1-FL will most likely outcompete it for binding to TPP1 and 
residency at telomeres, although this has not been formally shown with 
endogenous proteins. Furthermore, the potential dominant negative action of 
POT1-55 in exposing telomeres to DNA damage signaling must be repressed. 
Conversely, POT1-55 may function to facilitate telomere elongation, which could 
be important in cell types that proliferate extensively, but it must also be carefully 
regulated such that it does not confer immortal properties to an oncogenic 
transformed cell.  
6.3.3 Generation of telomeric overhangs 
In stark contrast to the extended overhangs observed in POT1a/b double 
knockout MEFs, and the reduction in overhangs after partial knockdown of 
human POT1, no change in overhang length was observed upon deletion of 
POT1-FL or POT1-FL/POT1-55. In light of the role of mouse POT1a and –b in 
overhang protection 152,153 and maintenance 31,32,52,177, and the existence of an 
overhang phenotype in human POT1 knockdown studies 184,185, it is highly 
improbable that POT1-FL is not involved in telomere 3’ overhang regulation. 
Instead, we favor the hypothesis that POT1 has a more complex, dual role in 
overhang generation, mediating both resection and fill-in synthesis.  
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The CST complex is required to generate telomeric 3’ overhangs 51-53, is 
proposed to inhibit telomerase activity, and interacts with human POT1 247,248. It 
is tempting to speculate that human POT1, similar to mouse POT1b, recruits 
CST to telomeres to generate overhangs of appropriate length by fill-in synthesis. 
If POT1 is required for CST recruitment to telomeres, depleting CST components 
with shRNAs should have no effect on overhang length in cells lacking POT1-FL. 
However, if CST associates with telomeres in the absence of POT1, depletion of 
CST may result in increased overhangs, allowing us to distinguish between the 
two possibilities. 
Telomere 3’ overhang signal increases transiently in S/G2 177,181 due to 
extensive resection by Exo1 52. While there is no evidence that POT1 and Exo1 
interact, it would be of interest to determine the changes in overhang signal after 
shRNA depletion of Exo1 in POT-FL knockout cells. No change in overhang 
signal would suggest Exo1 recruitment or activity is promoted by POT1. If POT1 
does not play a role in facilitating Exo1 action, we would expect to see a 
reduction in overhang signal. An alternate experiment to determine whether 
POT1 regulates Exo1 is to assess the transient increase in overhang length in 
S/G2, with the expectation of not detecting an increase if POT1 mediates Exo1 
recruitment.  
Based on studies in yeast 274,275, mammalian Exo1 is presumed to be 
recruited to DSBs after initial processing by the MRN complex, whereafter Exo1, 
in parallel with the BLM helicase, can extensively resect DSBs 125 124. Therefore, 
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it is possible that POT1 regulates a nuclease other than Exo1, or binds to as of 
yet undefined factors. However, the aforementioned experiments are likely to 
yield insights into the mechanism of overhang regulation by human POT1. Our 
observation of unchanged telomere overhangs upon loss of POT1 does not 
replicate the 30% decrease in overhang signal detected following treatment with 
an shRNA for POT1. A potential explanation of this discrepancy is that low levels 
of residual POT1 may be sufficient to recruit CST, but higher levels of POT1 are 
required to stimulate resection.  
Other hypotheses, albeit less likely, include overhang extension by TERT, 
and RPA-mediated regulation. Loss of POT1 may allow telomerase to extend 3’ 
overhangs, and fill-in synthesis could be mediated by CST, which can localize to 
telomeres independently of POT1 51. Steps upstream of ATR signaling may be 
involved in DNA overhang regulation. For instance, similar to its role in DNA 
repair, when POT1 is removed, perhaps RPA directs the 5’ to 3’ resection 276 at 
the telomere terminus and recruits Polα Primase 277 to perform the fill-in reaction.  
6.3.4 POT1 mutations - a compelling link between telomere dysfunction and 
disease 
Genomic sequencing studies in the past two years have identified 29 
heterozygous POT1 mutations (and counting) in cases of Chronic Lymphocytic 
Leukemia and Familial Melanoma 250-253. Majority of the mutations occur in the N-
terminal regions of POT1, within the DNA-binding OB folds, and are predicted to 
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act as dominant-negative alleles. There are also several C-terminal mutations 
that may prove interesting to investigate, as they may illuminate as yet unknown 
functions or binding partners of POT1. Additionally, the C-terminus of POT1 
contains the proposed interacting domains for CST and TPP1. Analysis of C-
terminal patient mutations may reveal separation-of-function mutants that are 
defective in single aspects of POT1 function. Several N-terminal mutations in 
POT1 have been characterized. Aside from observations of chromosomal 
abnormalities, fragile telomeres, and telomere lengthening, exact mechanisms of 
pathogenesis remain to be elucidated. The TALEN-mediated conditional 
knockouts of human POT1 will provide a useful resource to identify the 
dysfunctional phenotypes encoded by these mutations.  
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Chapter 7: Materials and Methods 
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7.1 General procedures 
7.1.1 Mammalian cell culture 
MEFs were isolated from E13.5 embryos and maintained in DMEM 
supplemented with 1 mM sodium-pyruvate, 100 U/mL penicillin, 0.1 µg of 
streptomycin per ml, 0.2 mM L-glutamine, 0.1 mM nonessential amino acids, and 
15% fetal bovine serum (FBS). Primary MEFs were immortalized by retroviral 
infection with pBabeSV40-LT (gift from Greg Hannon). 
HCT116, HT1080, ARPE-19, and HeLa1.3 cells were grown in Dulbecco 
modified Eagle medium (DMEM) supplemented with L-glutamine, penicillin-
streptomycin, nonessential amino acids and 15% bovine calf serum (BCS, 
HyClone). SV40-large T transformed (neo resistant) BJ fibroblasts were cultured 
in complete DMEM containing 199 medium (4:1) and 10% BCS.   
7.1.2 Retroviral gene delivery 
For infection of mouse cells, 24 h prior to transfection, 5x106 Phoenix 
ecotropic packaging cells were plated in 10 cm dishes. Phoenix cells were 
transfected with 20 μg of the appropriate plasmid by calcium phosphate 
precipitation. Media was changed 6-8 h after transfection. 36 h after transfection, 
media containing virus was collected, and filtered through 0.45 μM filter. 
Polybrene was added to a final concentration of 4 μg/mL. MEFs that had been 
plated 12-24 h earlier in 10 cm dishes and were ~40% confluent were infected. 3 
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infections were performed at 12 h intervals. Time zero was set at 12h after first 
infection. Infected cells were then selected for with the appropriate antibiotic 
(puromycin 2μg/mL, hygromycin 90μg/mL). Selection was deemed complete 
when uninfected control cells all died in the presence of antibiotic. 
For human cells, the above protocol was used with the following 
modifications. Phoenix amphotropic packaging cells were used to produce virus. 
Human cells were infected 3 times at 4 h intervals. Time zero was set at 12 h 
after first infection. Puromycin was used at 750 ng/mL, hygormycin was used at 
135 μg/mL. 
For infection with Cre recombinase, a Sloan Kettering facility produced 
virus from retroviruses pMMP Hit&Run Cre and pWZL Cre. The viruses were 
used to infect cells as described above. Selection with hygromycin followed 
infection with pWZL Cre. No selection was performed after treatment with 
Hit&Run Cre. 
For the tamoxifen-inducible Cre-ERT2 system, 500nM of 4-OHT was 
added to cells. Media was changed 6 h later and that was deemed time zero. 
7.1.3 Growth curves 
Growth curves were presented as population doublings over time and 
were calculated by the following formula: original PD + (ln(# cells counted/# cells 
seeded)/ln(2)). 
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7.1.4 Immunoblotting (IB) 
Immunoblotting was performed as previously described 22. Briefly, cells 
were harvested by trypsinization, resuspended in Laemmli buffer (100mM Tris-
HCl pH 6.8, 200 mM DTT, 3% SDS, 20% glycerol, 0.05% bromophenol blue) at 
10,000 cells per µl, denatured for 5 min at 95°C, sheared with an insulin needle, 
and resolved on SDS/PAGE gels using 100,000 cells per lane. Blots were 
blocked in 5% non-fat dry milk/PBS + 0.1% Tween20.  
7.1.5 Coimmunoprecipitation (Co-IP) from transfected 293T cells 
2 x 106 293T cells were plated 24 h before co-transfection with calcium 
phosphate co-precipitation using 10 µg each of FLAG-tagged and MYC-tagged 
constructs. Cells were harvested at 36 h after transfection, washed once with 
PBS, and lysed on ice for 10 min in a high salt buffer (50 mM Tris-HCl pH 7.2, 
400 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM EDTA, 1 mM DTT, 1 mM 
PMSF and cocktail of protease inhibitors). Salt concentration was brought down 
to 200 mM by addition of ice-cold water (drop-wise while mixing) and lysates 
were spun at 4°C at 14,000 rpm for 10 min. Supernatants were used in 
immunoprecipitations. 5% of the supernatant was saved as ‘input’ for western 
blot analysis and the remaining supernatant was pre-cleared with preblocked 
(10% BSA in PBS overnight) protein G-Sepharose beads for 1 h at 4°C. Lysates 
were incubated overnight at 4°C with a 40 µl slurry of Sepharose beads 
conjugated to 9E10-Myc or M2-FLAG mouse monoclonal antibody. Beads were 
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washed 5 times with ice-cold PBS. Proteins were eluted by boiling for 5 min in 
Laemmli buffer and analyzed by SDS-PAGE and immunoblotting. 
7.1.6 Immunofluorescence-fluorescence in situ hybridization (IF-FISH) 
IF-FISH was conducted as previously described 278. Briefly, cells grown on 
coverslips were fixed for 10 min in 2% paraformaldehyde/3% sucrose at room 
temperature, followed by three 5 min PBS washes. Coverslips were incubated in 
blocking solution (1 mg/ml BSA, 3% goat serum, 0.1% TritonX-100, 1 mM EDTA 
in PBS) for 30 min, followed by incubation with primary antibodies diluted in 
blocking solution for 1 h at rt. Cells were washed three times for 5 min with PBS 
and then incubated with secondary antibodies diluted in blocking solution for 30 
min at rt. Antibodies used were as listed at the end of this chapter. Coverslips 
were dehydrated with 70%, 95% and 100% ethanol and allowed to dry. 
Hybridizing solution (70% formamide, 0.5% blocking reagent from Roche, 10 mM 
Tris-HCl pH 7.2 and FITC-OO-(CCCTAA)3 or TAMRA-OO-[TTAGGG]3 PNA 
probe from Applied Biosystems) was added to each coverslip and denatured at 
80ºC for 5 min, followed by a 2 h incubation at rt. Two 15-min washes in 70% 
formamide/10 mM Tris-HCl pH 7.2 and three 5-min washes with PBS were 
performed. DNA was stained with DAPI in the PBS washes and coverslips were 
mounted using antifade reagent ProLong Gold from Life Technologies. Images 
were captured using a Zeiss AxioPlan II microscope with a Hamamatsu C4742-
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95 camera using Volocity software from Perkin Elmer. For distance of telomeres 
from nuclear membrane, calculations were made using Image J software. 
7.1.7 Telomeric FISH and chromosome orientation-FISH (CO-FISH) 
Telomeric FISH and CO-FISH were conducted as previously described 
119,154. Briefly, colcemid was added to cells 2 hours prior to harvest. Cells were 
collected by trypsinization, swollen in 0.075 M KCl and fixed overnight at 4ºC in 
methanol:acetic acid (3:1). Metaphase spreads were dropped on glass slides and 
aged overnight. Slides were hybridized with FITC-OO-[CCCTAA]3 or TAMRA-
OO-[TTAGGG]3 PNA probe in hybridizing solution, denatured at 80ºC for 5 min 
and incubated for 2 h at rt. Two 15-min washes in 70% formamide/10 mM Tris-
HCl pH 7.2 and three 5 min washes with 0.1 M Tris-HCl pH 7.2/0.15 M 
NaCl/0.08% Tween20 were performed. DAPI was added to last wash for DNA 
stain. Slides were dehydrated in 70%, 95%, and 100% ethanol and mounted 
using ProLong Gold antifade from Life Technologies. Images were captured 
using a Zeiss AxioPlan II microscope with a Hamamatsu C4742-95 camera using 
Volocity software from Perkin Elmer. For CO-FISH, BrdU:BrdC (3:1) was added 
14 h prior to harvest. Harvesting and metaphase conditions were as described for 
FISH. Slides were treated with 0.5 mg/ml RNase A diluted in PBS, stained with 
0.5 µg/ml Hoechst 33258, exposed to 5400J/m2 of UV light and subsequently 
digested with 800 U of Exonuclease III from Promega for 10 min at room 
temperature. Slides were rinsed with PBS, dehydrated with 70%, 95% and 100% 
 151 
ethanol and sequentially hybridized with TAMRA-OO-[TTAGGG]3 and FITC-OO-
[CCCTAA]3 for 2 h each at rt, without denaturation. Washing, mounting and 
capture conditions were as described for FISH. 
7.1.8 Chromatin immunoprecipitation (ChIP) 
ChIP was performed as previously described 79. Briefly, cells were fixed 
1% paraformaldehyde/culture medium for 45 min at room temperature. Glycine 
was added to 0.2 M to stop the cross-linking. Cells were pelleted by 
centrifugation and washed with ice-cold PBS, followed by a final wash in PBS/1 
mM PMSF. The cells were resuspended in cell lysis buffer (5 mM PIPES (pH 
8.0), 85 mM KCl, 0.5% Nonidet P-40, 1 mM PMSF, protease inhibitor cocktail 
from Roche), incubated on ice for 15 min and sonicated for 10 min (30 sec on/30 
sec off) in a water-bath sonicator. Supernatants of lysates were incubated with 
the appropriate antibody at 4 °C overnight and then for 45 min with ChIP-grade 
protein G magnetic beads (Dynal, Invitrogen). Immunoprecipitated DNA was 
washed, eluted from the beads, and precipitated with ethanol after reversal of the 
cross-links and Proteinase K treatment. The DNA samples were dissolved in 
water, boiled and loaded on dot blots, and hybridized with an 800-bp probe 
labeled with Klenow and a primer for the C-rich telomeric repeat strand. Signal 
intensity measured by ImageQuant software was normalized to the signals of the 
input DNA on the same blot. 
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7.1.9 Genomic blotting, telomere length and telomere overhang analysis 
Cells were harvested by trypsinization, washed with PBS, and either 
pelleted and frozen at -80ºC (for telomere length analysis) or processed 
immediately (for genotyping and telomere overhang analysis) for genomic DNA 
collection. Genomic DNA was extracted as previously described 4. DNA for 
genotyping was digested with appropriate enzymes, quantitated by fluorometry 
using Hoechst 33258 and 10 µg was loaded on a 0.7% agarose gel run in 0.5X 
TBE. DNA for telomere overhang and length analysis was digested with MboI 
and AluI, quantified using Hoechst, and 1 µg was run on 0.7% agarose gels in 
0.5X TBE.  
For genomic blots used for genotyping and telomere length analysis, the 
gels were depurinated with 0.5N HCl, denatured and neutralized using standard 
Southern blotting procedures and transferred as previously described 4. For 
genotyping, probes (indicated in figures) were Klenow-labeled using random 
primers and α-32P-dCTP. For telomere length analysis, a Sty11 probe with ~800 
bp of telomeric repeats 279 was Klenow-labeled with the TelC [CCCTAA]4 oligo 
and α-32P-dCTP. Membranes were exposed to PhosphorImager screens and 
quantified with ImageQuant software.  
For telomere overhang analysis, gels were dried and probed with a 
[CCCTAA]4 end-labeled with Polynucleotide kinase and γ-32P-ATP as previously 
described 280. The gel was washed at 55°C three times for 30 min each in 
4xSSC, once for 30 min in 4x SSC/0.1% SDS, and exposed to a PhosphoImager 
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screen overnight. After the image was captured, the gel was denatured in 0.5 M 
NaOH, 1.5 M NaCl for 30 min, neutralized with two 15 min washes in 0.5 M Tris-
HCl pH 7.5, 3 M NaCl, and hybridized overnight with the same probe at 55°C. 
The gel was washed and exposed as above. The ss G-rich overhang signal in 
the native gel was quantified with ImageQuant software and normalized to the 
total telomeric DNA quantified after the gel had been denatured and rehybridized 
with the telomeric probe. 
For telomere overhang analysis of mouse genomic DNA, 1x106 cells were 
resuspended in PBS and mixed 1:1 (v/v) with 2% agarose (SeaKem) in PBS and 
set in plug molds (BioRad). Plugs were digested overnight with Proteinase K 
buffer (10mM Tris-HCl pH 8.0, 250mM EDTA, 0.2% sodium deoxycholate, 1% 
sodium lauryl sarcosine), washed four times for 1 hr each with TE, with 1 mM 
PMSF in the last wash. Plugs were washed once more with H2O and digestion 
buffer. Plugs were incubated overnight at 37°C with 60 U MboI. The following 
day, the plugs were washed once in TE, and once in 0.5xTBE, and loaded onto a 
1% agarose/0.5xTBE gel. Samples were run for 24 hours on a CHEF-DRII PFGE 
apparatus (BioRad) in 0.5xTBE. The settings were as follows: initial pulse, 5 s; 
final pulse, 5 s; 6 V/cm; 14°C. Gels were dried and the same protocol outlined 
above was followed for hybridization, detection of signal, and quantification.  
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7.1.10 Northern analysis for TERRA 
Total RNA was prepared using RNeasy Mini Spin columns (QIAGEN) 
according to the manufacturer’s instructions and northern blot analysis was 
performed as previously described 281. Briefly, 20µg of RNA was loaded onto 
1.2% formaldehyde agarose gels and separated by gel electrophoresis. RNA was 
transferred to a Hybond-N+ membrane and crosslinked in a UV Stratalinker. The 
blot was prehybridized in Church mix at 55°C for 1 hour, followed by overnight 
hybridization with a Sty11 probe 279. The blot was washed 3 times for 15 minutes 
at 55°C with Church wash and then exposed to a Phosphorimager screen for 5 
days. Screens were scanned using ImageQuant software and quantified in Image 
J using the ethidium bromide stained 18S RNA as a loading control for 
normalization. 
7.1.11 Microarray analysis 
Total RNA was isolated from cell lines using RNeasy Mini spin columns 
(QIAGEN) with DNase digestion, according to the manufacturer’s instructions. 
Microarray hybridization and scanning were performed at the Genomics core 
facility at Rockefeller University, using Whole Human Genome DNA microarrays 
(Illumina HumanHT-12 v4). The data was analyzed using GeneSpring v12.6. 
Normalization was performed using quantiles and data was filtered to remove 
absent genes using flag calls.  
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Experiments for HT1080 and HCT116 cell lines were performed in 
replicate, using two independent isolations of RNA. Differentially expressed 
genes were identified after performing moderated T-Tests and applying the 
Benjamini-Hochberg False Discovery Rate method. A further fold change of 3 or 
2.75 was applied to the HT1080 and HCT116 clones respectively to identify 
genes that were highly transcriptionally deregulated due to the absence of Rap1. 
Microarrays for ARPE-19 were not performed in replicate and therefore an 
extremely stringent fold change threshold was applied to remove false negatives 
and identify differentially expressed genes, which were subsequently validated by 
qRT-PCR.  
7.1.12 Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
For qRT-PCR, cDNA was prepared from 1µg of total RNA by using 
Thermoscript Reverse Transcriptase (Invitrogen). Quantitative PCR reactions 
were performed using Life Technologies SYBR Green Master Mix on an Applied 
Biosystems 7900HT Sequence Detection System. Differences between samples 
calculated using QuantStudio software (Applied Biosystems) using the ΔCT 
method and were normalized to GAPDH.  
For human Rap1, two independent isolations of RNA and reverse 
transcriptase reactions were conducted and the experiment was repeated six 
times for clones 23, 25, 30 and the parental cell line. The experiment for clone 26 
was conducted in triplicate. For human POT1, qRT-PCR was conducted in 
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triplicate. Data was pooled to derive the mean averages and standard deviations. 
Significance was calculated using a two-tailed unpaired T-Test. Primers used are 
listed at the end of this chapter. 
7.1.13 Nickel-affinity purification of His-tagged proteins 
Human shelterin proteins were produced in baculovirus prior to this work20. 
Sf9 insect cells were infected with baculovirus expressing shelterin components 
for two days and purified as previously described 22. Briefly, infected cells were 
harvested and lysed in 5 ml of cold lysis buffer (50 mM Tris, pH 7.4, 150 mM 
NaCl, 1% Triton X-100, 5 mM β-mercaptoethanol supplemented with Roche 
Applied Science protease inhibitor mixture) per 100 ml of cell culture. All 
subsequent steps were done at 4 °C. After incubation on ice for 10 min, the 
mixture was sonicated and cleared by centrifugation at 13,200 rpm for 20 min. 
His tagged proteins were isolated using chelating Sepharose fast flow (GE 
Healthcare) nickel resin. Proteins were bound to the resin, washed and eluted 
with 1 M Imidazole. Protein yield and purity was quantified on SDS-PAGE gels 
against a BSA standard.  
7.1.14 Electrophoretic Mobility Shift Assays (EMSA) 
Binding reactions were conducted as previously described 20. Briefly, of 
EMSAs were conducted in in 4% Glycerol, 0.5 μgE. Coli DNA, 20 mM Glycine-
KOH [pH 9.0], 10 mM DTT, and 50 ng β-casein per 20 μl. Reaction with probe 
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and protein were incubated at 4°C for 30 min and run on a 0.6% agarose gel in 
0.1×  TBE at 4°C. Gels were dried onto DE81 paper and analyzed by 
autoradiography or by exposure on a Phosphorimager. DNA probes were 
prepared as described previously 11. In brief, the HindIII/Asp718 fragment 
containing (TTAGGG)12 repeats was purified from pTH12 11 and filled in with [α-
32P]dCTP and Klenow enzyme. Other probes used in this study were generated 
by annealing oligos (sequence is section 7.2), digesting with Asp718 and filling in 
with [α-32P]dCTP and Klenow. Dissociation constants were calculated using 
SigmaPlot by graphing % of bound probe against protein concentration.  
7.1.15 Genotyping and sequencing 
PCR was performed in 25 µl containing 50 ng of DNA, 0.2 µM of each 
primer, 0.1 µM dNTPs, 1.5 mM MgCl2, 50 mM KCl, 10 mM Tris-HCl pH 8.0, and 
0.5 U of TaKaRa Taq polymerase. Conditions were as follows: 95°C for 4 min, 25 
cycles of 95°C for 30 sec, 60°C for 30 sec, 72°C for 45 sec and final extension at 
72°C for 5 min.  
Sequencing of heterozygous clones to identify mutations was conducted 
by PCR-amplifying the remaining ‘WT’ allele. PCR products were eluted from 
agarose gels and sequenced. For sequencing of homozygous ‘WT’ clones, 
eluted PCR products were cloned by TA cloning (Life Technologies). A minimum 
of 8 resulting TA clones per cell line were sequenced to identify mutations in both 
alleles. 
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7.1.16 Gene targeting and cell cloning 
All cell lines were transfected in 10 cm dishes at a density of 3x106 cells 
using Lipofectamine 2000 (Life Technologies) with 4 µg of each TALEN construct 
and 20 µg of the appropriate donor construct. 48 hours after transfection, all cell 
lines, except for HeLa1.3, were plated in selection medium in 10 cm plates at 
varying densities ranging from 3,900 to 500,000 cells (using two-fold dilutions). 
HeLa1.3 cells were plated in 10 cm dishes using two-fold dilutions starting from 
8000 cells down to 75 cells. G418 was used at 1 mg/ml to select neomycin-
resistant HCT116 cells, at 900 µg/ml for HT1080 cells, and at 800 µg/ml for 
ARPE-19 cells. Blasticidin was used at 5 µg/ml for HT1080 and HeLa1.3 
selection, and at 2.5 µg/ml for SV40LT BJ selection. Zeocin was used at 
100µg/ml for HT1080 cells.  
For Rap1 targeting, clones emerged at a frequency of approximately 1 
clone per 500 plated HCT116 cells, 1 clone per 2,600 plated HT1080 cells, 1 
clone per 7,800 plated ARPE-19 cells, 1 clone per 125 plated HeLa1.3 cells, and 
1 clone per 62,500 plated SV40LT BJ cells. The media was not changed after 
initial plating. 
For POT1 targeting, clones emerged at a frequency of approximately 1 
clone per 3000 plated HT1080 cells in neomycin selection, 1 clone per 4000 
plated HT1080 cells in zeocin selection, and 1 clone per 15 plated HT1080 cells 
in blasticidin selection. 75% of HT1080 clones picked after blasticidin selection 
died after continuous culturing in blasticidin. 
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Clones were picked 12 days later for all cell lines except the SV40LT BJ 
clones, which were picked 3 weeks after plating. Approximately 60-70 clones 
were picked for each cell line using cloning cylinders from plates that contained 
well-spaced clones and the cells were transferred into 24 well plates. After 
reaching confluence, half of the cells in each well were harvested to extract 
genomic DNA, while the remaining cells were expanded into 6 well plates. 
Approximately 30-40 clones were screened per cell line. 
7.2 Mouse and human TERF2IP targeting 
7.2.1 Mouse TERF2IP targeting (by Agnel Sfeir) 
The Rap1 targeting vector was generated by cloning restriction fragments 
from a BAC clone into the pSL301 vector (Invitrogen). A neomycin cassette 
flanked by 2 FRT sites and containing a LoxP site was inserted into a CspCI site 
in the first intron. A second LoxP site, together with an NdeI site was introduced 
by inserting an oligonucleotide into a BsmBI site within the second intron. The 
vector was linearized with NotI and gene targeting of C57BL/6J ES cells was 
performed using standard techniques. ES cell clones with the correct integration 
were identified by southern blots of NdeI digested DNA using a 350-bp probe 
downstream of exon 3 outside the targeting vector. A correctly targeted ES clone 
was injected into C57BL/6J blastocyst to generate chimeric male founders. 
Crossing the chimeras to albino C57BL/6J females delivered offspring with the 
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Rap1F/+ genotype. Rap1 targeted mice were maintained in a C57BL/6J 
background. The neomycin cassette was deleted by crossing the mice to the 
FLPe-deleter mouse strain (Jackson Labs). The Rap1Δex2 allele was generated by 
crossing the Rap1F/+ to the E2a-Cre deleter strain (Jackson Labs). Rap1F/F mice 
were crossed with Ku70-/+ mice (obtained from F. Alt, Harvard Medical School, 
Boston MA). 
7.2.2 TALENs and the TERF2IP targeting construct 
The heterodimeric TALEN pair for TERF2IP targeting was constructed 
using the following RVD sequences. LEFT2: 5’-HD-NG-NN-NG-NN-HD-NG-NN-
NG-NG-HD-NG-NG-HD-NG-HD-NG, RIGHT1: 5’-HD-NG-NN-NN-NI-NN-NG-NG-
HD-NG-HD-NG-NG-NI-NG-NG-3’. TALENs were constructed by Dirk 
Hockemeyer. The PGK Neomycin cassette from the PL451 vector (NCI) was 
liberated using restriction enzymes NheI (5’) and BstBI (3’) and ligated into NheI- 
and BstBI- digested pSL301 (cloning vector from Invitrogen). The pEF Blasticidin 
cassette from plasmid pEF/Bsd (Life Technologies) was released using NheI (5’) 
and EcoRI (3’) and ligated into NheI- and EcoRI- digested pSL301. The 5’ and 3’ 
homology arms were PCR-amplified with restriction site overhangs from genomic 
SV40LT BJ fibroblast DNA. Primers for PCR of the 5’ arm were as follows: 5’-
ATGCGGTACCTTGCCCAAACTCCTGTCTTCTTAGGGC-3’ and 5’-
GCATGCTAGCAGAGAAGAACAGCACAGATTAGCAATAGCC-3’. Primers for 
PCR of the 3’ arm were 5’-
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ATGCTTCGAACTAGATTTACTCATTATTTTTTTCCCTACC-3’ and 5’- 
GCATTTCGAACCTGTAATCCCAGCACTTTGGGAG-3’. The resulting 600 bp 5’ 
homology arm ends 7 bp from the intron 1/exon 2 junction and has KpnI and 
NheI sites on the 5’ and 3’ ends, respectively. The resulting 578 bp 3’ homology 
arm starts 32 bp from the exon 2/intron 2 junction and has BstBI restriction sites 
at both ends. The homology arms were cloned into the relevant restriction sites in 
pSL301 containing either the PGK Neomycin or pEF Blasticidin. The 3’ homology 
arm insertion was screened for orientation and the donor constructs were 
sequenced using the following primers: T7, T3, 5’-
GCTCGCGTCGTGCAGGACGT-3’ (PGK internal primer), and 5’- 
GCTGTGCTCGACGTTGTCAC-3’ (Neomycin internal primer). 
7.3 POT1 gene targeting 
7.3.1 TALENs and the POT1 targeting construct 
The heterodimeric TALEN pair for POT1 targeting was constructed using 
the following RVD sequences. LEFT: 5’-NI-NI-NI-NI-NG-NI-NG-NG-NN-NI-NI-NI-
NN-NG-HD-NI-NN-3’, RIGHT: 5’-NN-NI-NN-HD-NI-NI-NG-NI-NI-NG-HD-NG-NN-
NN-NI-3’. TALENs were constructed by Siobhan Gregg, Supawat Thongtip and 
Shaheen Kabir using the FLASH assembly system (REYON REF). The PGK 
Neomycin cassette from the PL451 vector (NCI) was liberated using restriction 
enzymes NheI (5’) and BamHI (3’) and ligated into NheI- and BamHI- digested 
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pSL301 (cloning vector from Invitrogen). The SV40 Zeocin cassette from 
pSV40/Zeo2 (Invitrogen) was liberated using restriction enzymes NheI (5’) and 
BamHI (3’) and ligated into NheI- and BamHI- digested pSL301. The pEF 
Blasticidin cassette from plasmid pEF/Bsd (Life Technologies) was released 
using NheI (5’) and BamHI (3’) was liberated using restriction enzymes NheI (5’) 
and BamHI (3’) and ligated into NheI- and BamHI- digested pSL301. The pEF 
promoter of the blasticidin cassette was replaced with a PGK promoter by cloning 
it out of PL451 by NheI/XbaI digest and cloning it into NheI-digested pEF 
blasticidin. The STOP cassette was digested out of Lox-Stop-Lox TOPO 
(available from Addgene, Tyler Jacks lab) with BamHI and EcoRI and cloned into 
the relevant sites of the neomycin, blasticidin and zeocin donor constructs. The 5’ 
and 3’ homology arms were PCR-amplified with restriction site overhangs from 
genomic HT1080 DNA. Primers for PCR of the 5’ arm were as follows: 5’-
CTACCACCAGTGTTTGAAGTTATCG-3’ and 5’- 
AATATTTTACCTGACTTTCAATATTTTAAAGC-3’. Primers for PCR of the 3’ arm
were 5’- CTCTGTATTGTTCACTGAAACTAGTTAGCAC-3’ and 5’-
CCAGAAGTGCATTGAACAAAAAAGCTC-3’. The resulting 647 bp 5’ homology
arm ends 14 bp from the intron 2/exon 3 junction and has XhoI and NheI sites on 
the 5’ and 3’ ends, respectively. The resulting 649 bp 3’ homology arm starts 43 
bp from the exon 3/intron 3 junction and has EcoRI restriction 5’ and a blunt 3’ 
end. The homology arms were cloned into the relevant restriction sites in pSL301 
containing either the PGK Neomycin or pGK Blasticidin or pSV40 Zeocin. 
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7.4 List of primers 
7.4.1 Genotyping 




Human Rap1 primers: 





PGK internal primer: 
R2: 5’-CATCTGCACGAGACTAGTGAGACGTGCTAC-3’ 
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Zeocin internal primer: 
R4: 5’-GAGCACCGGAACGGCACTGGTCAACT-3’
7.4.2 RT-PCR 













POT1 coding exon 2 (anneals to both isoforms)
5’-CACCCCTGAATCAACTTAAGGGTGG-3’ 
POT1 coding exon 3 (anneals only to POT1-FL) 
5’-CTGGTCCACAATAGTTACAACTGAGC-3’ 
POT1 coding exon 2-4 junction (anneals only to POT1-55) 
5’-TATACTTGAATCAGTTCCTTTGC-3’ 
POT1 coding exon 4 (anneals to both isoforms) 
5’-GCTCCGTCCACTTCTGCTTTGCCCA-3’ 
POT1 coding exon 9 (anneals to both isoforms) 
5’-CAGACTGAAATAGTCTTCTGGGC-3’ 
POT1 coding exon 13 (anneals to both isoforms) 
5’-CCATGAGATAGGCTTCTAGTACTCC-3’ 
POT1 coding exon 15 (anneals to both isoforms) 
5’-CATCTTCTGCAACTGTGGTGTC-3’
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7.5 List of shRNAs 
Mouse TPP1: 
Target sequence 5’-GGACACATGGGCTGACGGA-3’ 
Mouse Rap1: 
sh1 target sequence 5’- ACAGGCAATGCCTTGTGGAAA -3’ 
sh2 target sequence 5’-CTTCATCTCCA CGCAGTACAT-3’ 
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7.6 List of antibodies 
Antigen ID Source Uses 
hRap1 765 de Lange lab ChIP, IB 
hTRF2 647 de Lange lab ChIP 
hTRF1 371 de Lange lab ChIP 
hTIN2 864 de Lange lab ChIP 
POT1 ab124784 Abcam IB, ChIP 
hTPP1 1151 de Lange lab ChIP 
mRap1 1252 de Lange lab IB, IF, ChIP 
mTRF2 1254 de Lange lab IB, ChIP 
mTRF1 1449 de Lange lab IB, ChIP 
mTIN2 1447 de Lange lab IF, ChIP 
POT1a 1221 de Lange lab IB, ChIP 
POT1b 1223 de Lange lab IB, ChIP 
MYC 9E10 Calbiochem IB, IP 
MYC 9B11 Cell signaling IF, ChIP 
FLAG M2 Sigma IB, IP, IF 
53BP1 100-304 Novus IF 
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Lamin A L1293 Sigma IF 
Alpha-tubulin T9026 Sigma IB 
Chk2 611570 BD Transduction IB 
Chk1-P Ser345 Cell Signaling IB 
Chk1 Sc-8408 Santa Cruz IB 
H3K9me1 ab9045 Abcam ChIP 
H3K9me2 ab1220 Abcam ChIP 
H3K9me3 ab8898 Abcam ChIP 
HP1alpha ab77256 Abcam ChIP 
HP1beta ab10478 Abcam ChIP 
HP1gamma ab10480 Abcam ChIP 
Acetyl Histone H4 06-598 Millipore ChIP 
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7.7 List of cell lines 
Cell Line Organism, Organ Notes 
TRF2F/- p53-/- Mouse, E13.5 MEFs 
24
TRF2F/F Ku70-/- Mouse, E13.5 MEFs 
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Rap1F/F Mouse, E13.5 MEFs This work 
Rap1Δex2/ Δex2 Mouse, E13.5 MEFs This work, Agnel Sfeir 
Rap1F/F Ku70-/- Mouse, E13.5 MEFs This work 
Rap1F/F Ku70+/- Mouse, E13.5 MEFs This work 
Rap1F/Δex2 Ku70-/- Mouse, E13.5 MEFs This work 
TRF1F/F Cre-ERT2 Mouse, E13.5 MEFs Agnel Sfeir 
HT1080 Human, Fibrosarcoma ATCC 
HCT116 Human, Colorectal 
carcinoma 
ATCC 
ARPE-19 Human, Retinal pigment 
epithelial  
ATCC 
BJ Human, foreskin ATCC 
HeLa1.3 Human, Cervical 
adeoncarcinoma 
22
Phoenix ecotropic Human, Epithelial 
Phoenix amphotropic Human, Epithelial 
293T Human, Kidney 
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